

Curriculum Vitae and Bibliography

Johan Auwerx
M.D., Ph.D.

PART 1: General Information

Name: Johan (first), Henri (middle) AUWERX

Office Address:

Ecole Polytechnique Fédérale de Lausanne
1015 Lausanne
Switzerland

Home Address:

17 Route des Deux Communes
1164 Buchillon
Switzerland

Work E-mail: johan.auwerx@epfl.ch

Work phone: +41-21 693 95 22 (admin assistant)
+41-21 693 09 51 (direct)

Work fax: +41-21 693 96 00

Place of birth: Diepenbeek, Belgium

Education:

<i>Year</i>	<i>Degree</i>	<i>Institution</i>
1967-1975	College (Summa cum laude)	St-Jozefscollege, Hasselt, Belgium
1975-1978	Bachelor Medical Sciences (Magna cum laude)	Katholieke Universiteit Leuven, Belgium
1978-1982	Medical Doctor (M.D.; Summa cum laude)	Katholieke Universiteit Leuven, Belgium
1986-1990	Doctor of Philosophy (Ph.D.) Dissertation: <i>Regulation of genes involved in lipid metabolism in the macrophage</i>	Katholieke Universiteit Leuven, Belgium

Post-doctoral training:

<i>Year</i>	<i>Title</i>	<i>Specialty/Discipline</i>	<i>Place of Training</i>
1986	Research Fellow	Molecular Endocrinology	Katholieke Universiteit Leuven, Belgium
1986-1989	Research Fellow	Molecular Endocrinology	University of Washington, Seattle, WA
1989	EMBO Fellow	Molecular Biology	Laboratoire de Génétique Moléculaire

des Eucaryotes, Strasbourg, France

Licensure and Certification:

<i>Year</i>	<i>Type of License or Certificate</i>
1982	License as Medical Doctor, Belgium
1982	ECFMG (Educational Commission for Foreign Medical Graduates) certificate on basis of the VISA qualifying examination (certificate # 352-705-8)
1987	License as Specialist in Internal Medicine, Belgium
1991	License as Medical Doctor, France

Academic Appointments:

<i>Year</i>	<i>Academic Title</i>	<i>Institution</i>
1988-1991	Research Associate	NFWO, Katholieke Universiteit Leuven, Belgium
1991-1999	Research Director (~ Full Professor)	CNRS, Institut Pasteur de Lille, France
1999-2003	Research Director (~ Full Professor)	CNRS, Institut de Génétique et Biologie Moléculaire et Cellulaire, Illkirch, France
2003-2008	Professor of Medicine	Université Louis Pasteur, Strasbourg, France
2007-	Visiting Professor	Harvard Medical School, Boston, MA
2008-	Full Professor	Ecole Polytechnique Fédérale Lausanne, Switzerland

Hospital or Affiliated Institution Appointments:

<i>Year</i>	<i>Title</i>	<i>Hospital or Affiliated Institution</i>
1982-1985	Resident in Medicine	University Hospital Gasthuisberg, Leuven, Belgium
1985-1986	Fellow in Endocrinology & Metabolism	University Hospital Gasthuisberg, Leuven, Belgium
1986-1988	Fellow in Endocrinology & Metabolism	University of Washington, Seattle, USA
1988-1991	Consultant Endocrinology & Metab.	University Hospital Gasthuisberg, Leuven, Belgium

Other Professional Positions and Major Visiting Appointments:

<i>Year</i>	<i>Position/Title</i>	<i>Institution</i>
2002-2006	Co-Director	Institut Clinique de la Souris, Illkirch, France
2006-2008	Director	Institut Clinique de la Souris, Illkirch, France

Hospital and Health Care Organization Service Responsibilities:

None

Major Administrative Responsibilities:

<i>Year</i>	<i>Title</i>	<i>Institution</i>
2002-2006	Co-Director	Institut Clinique de la Souris, Illkirch, France
2006-2008	Director	Institut Clinique de la Souris, Illkirch, France

Major Committee Assignments:

<i>Year</i>	<i>Name</i>	<i>Role</i>	<i>Institution</i>
1998-2000	Study section #25	Member	CNRS, Paris, France
2004-2005	Study section 6 th EU FP	Member	EU RTD, Brussels, Belgium

Professional Societies:

<i>Year</i>	<i>Society</i>	<i>Role</i>
1989-	American Heart Association	Foreign Member
1995-	Endocrine Society	Foreign Member
2003-	EMBO	Elected Member in 2003

Community Services Related to Professional Work:

<i>Year</i>	<i>Position/Title</i>	<i>Role</i>	<i>Institution</i>
1995-2001	SAB Member	Advisory	Ligand Pharmaceuticals, San Diego, CA
2002-2004	Founder & SAB member	Advisory	Carex S.A., Strasbourg, France
2004-2006	Scientific advisor	Advisory	SK Bio-Pharmaceuticals, Fairfield, NJ
2004-2008	SAB Member	Advisory	Sirtris Pharmaceuticals. Boston. MA
2005-2006	Ad hoc SAB member	Advisory	Keystone Symposia, Keystone, CA
2006-	Founder & SAB member	Advisory	PhytoDia, Strasbourg, France
2006-	SAB member	Advisory	Intercept Pharmaceuticals, NY, NY

Editorial Boards:

<i>Year</i>	<i>Role</i>	<i>Name</i>
2001-	Editorial board member	Annals of Medicine (ISI impact factor: 5.779)
2003-2005	Editorial board member	Journal of Clinical Endocrinology and Metabolism (ISI impact factor: 5.493)
2004-2007	Editorial board member	Molecular Endocrinology (ISI impact factor: 5.337)
2004-2009	Editorial board member	Drug Discovery Today (ISI impact factor: 4.411)
2004-2008	Editorial board member	BioMed Central Molecular Biology (ISI impact factor: 3.115)
2004-	Associate editor	Cell Metabolism (ISI impact factor: 17.148)
2007-	Editorial board member	Endocrine reviews (ISI impact factor: 18.493)
2008-	Editorial board member	EMBO Journal (ISI impact factor: 8.662)
2008-	Editorial board member	EMBO reports (ISI impact factor: 7.450)
2008-	Editorial board member	Cell (ISI impact factor: 29.887)

Awards and Honors:

<i>Year</i>	<i>Name of the Award</i>
1985	Horlait-Dapsens prize for medical research; Belgium
1986	NATO travel grant; NATO countries
	Fellowship Belgian American Educational Foundation; USA/Belgium
	Fullbright award; USA
	Travel award Belgian National Foundation for Research; Belgium
1987	J.Fogarty international research fellowship (NIH); USA
1989	F. De Waele prize for cancer research; Belgium
	Morgagni Young Investigator Award on Metabolism; Italy
	Boehringer-Mannheim prize for Atherosclerosis; Belgium
1992	Belgian Endocrine Society Award; Belgium
1993	Prix Danone "Santé et Nutrition"; France
1998	Prix de la Fondation pour la Recherche Médicale; France
	Minkowski Prize, European Association for the Study of Diabetes; Europe (Euro).
	Spa Prize for Nutrition; Belgium
2001	6 th Dalan Boyd Pritchett Lecture, University of Pennsylvania, PA
2003	EMBO member.
2004	Morgagni Gold Medal for Metabolism: Italy
2005	Prix Jean Valade de la Fondation de France

2006 Josiah Brown Lecture Award, UCLA, CA

PART II: Research, Teaching, and Clinical Contributions

A. Narrative report of research and teaching

My **research** (~70% effort) aims to understand, by using an integrative functional genomic approach, how nuclear receptors (NRs) and their associated cofactors control metabolism and how their aberrant function contributes to the pathogenesis of complex metabolic disorders, such as obesity and type 2 diabetes. These complex metabolic diseases result from the combined action of many genes and environmental factors, such as diet or exercise. Our present challenge is to sort out how these contributing factors interact so as to develop effective strategies for diagnosis, prevention, and therapy of these diseases. Biology, genomics, computation, and statistics are now sufficiently mature to address these issues in a holistic context of an experimental model system, such as the mouse, and to adapt an integrative (systems) approach to address these questions. Genetic and environmental factors that affect homeostasis usually change gene expression, ultimately resulting in metabolic adaptation. This is why we selected to study NRs and associated transcriptional coregulators, which are especially well positioned to translate the impact of genetic and environmental perturbations into changes in gene expression.

Our work on the peroxisome proliferator activated receptor γ (*PPAR γ*) led to the concept of PPAR γ modulators, which recruit distinct sets of transcriptional coactivators. This could ultimately translate in PPAR γ ligands with an improved efficacy and therapeutic window. We furthermore expanded the therapeutic arena of PPAR γ ligands to the treatment of inflammatory syndromes, cancer, and osteoporosis, all areas of intensive clinical investigation at present. Furthermore, we discovered an association between the PPAR γ Pro12Ala gene variant with type 2 diabetes and obesity, which we identified long before the era of genome-wide association studies, and as such PPAR γ became the first gene tied with these common complex diseases. Our group was involved in the demonstration of how the *enterohepatic nuclear receptors*, liver receptor homolog-1 (LRH-1) and short heterodimeric partner (SHP) are involved in the homeostatic control of cholesterol, triglyceride and bile acid metabolism and in the identification of bile acids as endocrine regulators of energy expenditure, via a novel membrane bile acid receptor, *TGR5*, a potential anti-obesity drug target.

We furthermore contributed to the understanding of cofactor biology by showing that the *SRC-2 and -3* cofactors play an important role in the control of whole body energy homeostasis by acetylating and reducing the activity of PGC-1 α the master regulator of oxidative phosphorylation. Most recently, we became interested in the sirtuin family of NAD⁺-dependent histone deacetylases, composed of 7 members in mammals. We demonstrated that the activation of *SIRT1* by the polyphenol resveratrol or the synthetic SIRT1 activating compound, SRT1720, improves energy expenditure and metabolic homeostasis, by deacetylating and activating PGC-1 α thereby providing thereby a mechanism by which resveratrol/SIRT1 achieves its beneficial effects on longevity.

Although my research involves the elucidation of fundamental biological mechanisms, I am always preoccupied with the clinical relevance of my work. My clinical inspiration motivated me to participate at the highest level in the *Institut Clinique de la Souris* (ICS, Illkirch) and the *Center of PhenoGenomics* (CPG, EPFL, Lausanne), both state-of-the-art mouse functional genomics institutes devoted to the generation and analysis of mouse disease models. In this context, I contributed in a substantial fashion to several European mouse functional genomics networks.

I divide ~30% of my time between two **teaching activities**: 1) the supervision of master/graduate students and post-doctoral fellows; 2) teaching “integrative metabolism” to medicine and biology students.

B. Funding Information

The funding is all destined to support research activities.

<i>Years Covered</i>	<i>Funding Source</i>	<i>PI/CoPI</i>	<i>Grant Title</i>
1992-1998	Inserm, France	PI	Functional characterization of PPAR γ
1998-2002	ARC (#9943)	PI	Regulation of PPAR γ transcriptional activity
1998-2006	CNRS/Inserm, France	PI	Orphan Nuclear Receptors: structure and function
1999-2001	JDRF	PI	The role of the PPAR γ NH2 terminus
1999-2002	HFSP	PI	Characterization of nuclear orphan receptors
2000-2004	EU 5 th framework, RTD	CoPI	Functional genomics of type 2 diabetes (Eugene)
2001-2002	ARERS	PI	PPAR γ and insulin sensitization
2001-2006	NIH (P01 DK59820)	CoPI	Genetic and metabolic fingerprints of SRC coactivators
2002-2005	EU 5 th framework, RTD	CoPI	Mouse functional genomics (Eumorphia)
2003-2004	ARC (#5800)	PI	Regulation of PPAR γ transcriptional activity (#2)
2003-2006	French Research Ministry	PI	Mouse models for the nuclear receptor LRH-1
2004-2006	French Research Ministry	PI	A mouse model with muscle-specific SIRT1 deficiency
2004-2008	EU 6 th framework, RTD	CoPI	Functional genomics of type 2 diabetes (Eugene2)
2005-2007	AFM	CoPI	Mouse model with CNS-specific LRH-1 deficiency
2005-2010	NIH (R01 DK67320)	PI	Phenogenomics of human PPAR γ mutations
2005-2007	ARC (#3660)	CoPI	LRH-1 & SHP in of colon cancer
2005-2007	ARC (#3689)	PI	The cofactor SRC-3 in lymphoma development
2005-2008	EU 6 th framework, RTD	CoPI	Systematic mouse mutagenesis program (EUCOMM)
2006-2008	French Research Ministry	CoPI	The role of LRH-1 in the enterohepatic axis
2006-2011	NIH (P01 DK59820)	CoPI	Genetic and metabolic fingerprints of SRC coactivators
2007-2011	EU 6 th framework, RTD	CoPI	Mouse disease clinics (EUMODIC)
2009-2014	ERC Advanced Grant	PI	The phenogenomics of the sirtuin gene family (Sirtuins)

C. Report of Current Research activities other than those mentioned above

None.

D. Report on Teaching**1. Local Contributions****a. Medical students: School of Medicine at the Université Louis Pasteur, Strasbourg, France**

Years taught: 2002, 2003, 2004, 2005, 2006

Name of the course: Integration of metabolism

Description of teaching role: lecturer

Type and average number of students: ~400-500 2nd year medical students

Amount of preparation and contact time involved: 1 week preparation time; 2 hr course

Years taught: 2005, 2006

Name of the course: Cholesterol synthesis and removal

Description of teaching role: lecturer

Type and average number of students: ~500 2nd year medical students

Amount of preparation and contact time involved: 1 week preparation time; 1 hr course

Years taught: 2005, 2006

Name of the course: Bile acid homeostasis

Description of teaching role: lecturer

Type and average number of students: ~500 2nd year medical students

Amount of preparation and contact time involved: 1 week preparation time; 1 hr course

Years taught: 2005, 2006

Name of the course: Energy homeostasis and metabolic diseases (type 2 diabetes, obesity)

Description of teaching role: lecturer

Type and average number of students: ~500 2nd year medical students

Amount of preparation and contact time involved: 1 week preparation time; 1 hr course

b. Graduate Medical Courses: School of Medicine at the Université Louis Pasteur, Strasbourg, France

Years taught: 2003, 2004, 2005, 2006

Name of the course: pathophysiology of obesity and type 2 diabetes

Description of teaching role: lecturer

Type and average number of students: ~100 3rd year medical students and ~50 Pharmacy students

Amount of preparation and contact time involved: 1 week preparation time; 2 hr course

g. Names of advisees or trainees:

The following scientists spent significant amount of time in my laboratory either during their Master of Science (M.Sc) program (1-2 years), during their Ph.D. training (3-4 years), or performed a post-doctoral fellowship in my laboratory.

<i>Duration of training</i>	<i>Name</i>	<i>Degree obtained</i>	<i>Current Position</i>
1988-1991	Bart Staels	Ph.D.	Institut Pasteur, Lille, France
1991-1995	Kristina Schoonjans	Ph.D.	INSERM, Illkirch, France
1992-1993	Christel Aperlo	M.Sc.	CNRS, Nice, France
1992-1993	Roser Busca, Ph.D.	Post-Doc	CNRS, Nice, France
1992-1996	Jean-Pierre Bossu	Ph.D.	Fischer, Illkirch, France
1992-1996	Regis Saladin	Ph.D.	Phytodia, Illkirch, France
1993	Anne-Catherine Robert	M.Sc.	Lyon, France
1994-1998	Anne-Marie Lefebvre	Ph.D.	Sanofi-Aventis, Paris, France
1994-1998	Genevieve Martin	Ph.D.	Genfit, Lille, France
1995	Laurence Suaud	M.Sc.	Genfit, Lille, France
1995-1996	Yvonne Anderson, Ph.D.	Post-Doc	Umea University, Sweden
1995-1996	Philippe Gervois	M.Sc.	Institut Pasteur, Lille, France
1995-1996	Yannick Delplace	M.Sc.	Genfit, Lille, France
1995-1997	Piet Devos, Ph.D.	Post-Doc	PGS, Ghent, Belgium
1995-1998	Eric Raspe, Ph.D.	Post-Doc	Genfit, Lille, France
1995-1999	Nathalie Hennuyer	Ph.D.	Institut Pasteur, Lille, France
1995-2001	Lluis Fajas, Ph.D.	Post-Doc	INSERM, Montpellier
1996-1997	Corinne Ballaster	M.Sc.	INSERM, Marseille, France
1996-1997	Thierry Claudel	M.Sc.	Institut Pasteur, Lille, France
1996-2000	Laurent Gelman	Ph.D.	FMI, Basel, Switzerland
1997-1998	Hilde Sundvold, Ph.D.	Post-Doc	University of Oslo, Norway
1998-1999	Celine Talon	M.Sc.	Institut Pasteur, Lille, France
1998-1999	Laurent Dubuquoi	M.Sc.	INSERM, Lille, France
1998-1999	Mathilde Dubois	M.Sc.	INSERM, Lille, France

1998-2001	Stephane Rocchi, Ph.D.	Post-Doc	INSERM, Nice, France
1998-2002	Carole Brendel	Ph.D.	Amylin, San Diego, CA
1998-2002	Oronzina Botrugno	Ph.D.	University of Milano, Italy
1999-2000	Karen Van Herck	M.Sc.	CNRS, Lyon, France
1999-2000	Gordon Francis, M.D.	Visiting Prof.	University of Calgary, Canada
1999-2000	Raphael Streiff, M.D.	Post-Doc	GlaxoSmithKline, USA
1999-2001	Frederic Picard, Ph.D.	Post-Doc	Université de Laval, Canada
1999-2001	Viviane Egler	M.Sc.	FMI, Basel, Switzerland
1999-2003	Céline Haby	Ph.D.	INSERM Lyon, France
2000-2003	Svetlana Morozowa	Ph.D.	Solvay, Brussels, Belgium
2000-2004	Marie-Bernard Debril	Ph.D.	University Lausanne, Switzerland
2001-2002	Rima El Takesh	M.Sc.	ULP, Strasbourg, France
2001-2002	Stine Ulven, Ph.D.	Post-Doc	University of Oslo, Norway
2001-2003	Terrie-Ann Cock, Ph.D.	Post-Doc	GlaxoSmithKline, UK
2001-2004	Elisabeth Fayard	Ph.D.	FMI, Basel, Switzerland
2001-2004	Jean-Sebastien Annicotte	Ph.D.	INSERM Montpellier, France
2001-2004	Mitsuhiro Watanabe	Ph.D.	Keio University, Tokyo, Japan
2003-2004	Taouifiq El-Harach	M.Sc.	Nestle, Vevey, Switzerland
2003-2006	Carmen Argmann, Ph.D.	Post-Doc	Rosetta Inpharmatica, Seattle, USA
2003-2006	Carole Mette	Ph.D.	Roche, Basel, Switzerland
2003-2006	Sebastien Goetz	Ph.D.	ULP, Strasbourg, France
2003-2007	Sebastien Froehlich	Ph.D.	ULP, Strasbourg, France
2003-2007	Nassim Dali-Youcef	Ph.D.	ULP, Strasbourg, France
2003-2007	Agnes Coste	Ph.D.	Université de Toulouse, France
2004-2007	David Volle	Ph.D.	INSERM Nice, France
2004-2007	Romain Barnouin	Ph.D.	PhytoDia, Illkirch, France
2004-2007	Benjamin Magnier	Ph.D.	Sanofi-Aventis, Montpellier, France
2004-2008	Raj Dugavatti, D.V.M.	Post-Doc	University of Montreal, Canada
2004-2008	Chikage Matakai, Ph.D.	Post-Doc	University of Tokyo, Japan
2005-2008	Sami Heikkinnen, Ph.D.	Post-Doc	University of Washington, Seattle, USA
2005-2008	Hiroyasu Yamamoto, M.D.	Post-Doc	EPFL, Lausanne, Switzerland
2005-2008	Hiroyuki Sato	Ph.D.	University of Osaka, Japan
2005-2008	Marie Lagouge	Ph.D.	University of Basel, Switzerland
2006-2008	Charles Thomas, Ph.D.	Post-Doc	EPFL, Lausanne, Switzerland
2006-2006	Jerome Feige, Ph.D.	Post-Doc	University of Basel, Switzerland
2007-2009	Carles Canto, Ph.D.	Post-Doc	
2008-2010	JiuJiu Yu, Ph.D.	Post-Doc	
2007-2009	Axelle Strehle	Ph.D.	PhytoDia, Illkirch, France
2009-2011	Richardus Houtkooper, Ph.D.	Post-Doc	

2. Regional, National, or international contributions

a. Invited presentations

1991

- Invited speaker; Meeting of the Arcol, Paris, France
- Invited speaker; Milano International Meeting on Diabetes, Milano, Italy
- Poster presentation; UCLA Symposium on Steroid Hormone Receptors, Steamboat Springs, USA
- Invited Speaker; Gene Expression during Liver Differentiation and Disease, Sorrento, Italy
- Oral presentation: American Heart Association, Anaheim, USA

1992

- Invited speaker; European Atherosclerosis Society Meeting, Nice, France
- Invited speaker; Symposium on Atherosclerosis and its cardiovascular complications, New Brunswick, USA
- Invited speaker; First Fournier Workshop on Molecular Biology of Atherosclerosis, Meribel, France
- Invited speaker; Belgian Endocrine Society Lecture, Brussels, Belgium
- Invited speaker; Lipids, lipoproteins and Atherosclerosis, Helsinki, Finland

1993

- Invited speaker; Colloque de la Société de Biologie Cellulaire de France, Lyon, France
- Invited speaker; European Atherosclerosis meeting, Jerusalem, Israel
- Poster presentation; American Heart Association, Atlanta, USA
- Invited speaker; FEBS meeting on peroxisomes, Dijon, France
- Invited speaker; ARCOL meeting, Paris, France
- Invited speaker; Meeting on Peroxisomal Disorders, Amsterdam, Holland

1994

- Invited speaker; British Endocrine Society, Bournemouth, UK (invited speaker).
- Invited speaker; International Atherosclerosis Society, Montreal, Canada
- Invited speaker; International Symposium "Therapeutic Strategies in Dyslipidemia", Monte-Carlo
- Invited speaker and session chairman; Bioavenir Symposium, Marne-LaVallée, France
- Poster presentation; American Heart Association meetings, Dallas, USA

1995

- Invited speaker; American Association for Cancer Research meeting on Steroid Receptors, Whistler, Canada
- Oral presentation; American Heart Association meetings, Anaheim, CA, USA
- Invited speaker; Deuel Conference on Lipids, Monterey, CA, USA
- Invited speaker; First Gencell meeting on Gene therapy, Philadelphia, PA, USA
- Invited speaker; Association Franco-Autrichien pour la recherche sur les Lipides, Nice, France
- Invited speaker and chairman; Biotechnology Symposium: "Nuclear Orphan Receptors, Stockholm, Sweden
- Invited speaker; 2nd Japan Europe Forum on Atherosclerosis, Nice, France
- Invited speaker; ILSI workshop on Peroxisome Proliferation, Washington, DC, USA

1996

- Invited speaker; Japanese Atherosclerosis Society, Osaka, Japon
- Invited speaker; Durnsteiner Atherosclerose Tagen, Durnstein, Autriche
- Invited speaker; European Atherosclerosis Society, Firenze, Italie
- Invited speaker; Dyslipidemies familiales (jubilé du Prof. J-L De Gennes), Paris, France
- Invited speaker; Euroconferences de L'Institut Pasteur, Paris, France
- Invited speaker; Xème Journée de Nutrition et de Thérapeutique, Bordeaux, France
- Invited speaker; XIVème Congres de la Société Francaise d'Endocrinologie, Angers, France
- Invited speaker; Keystone Symposium "Steroid/thyroid/retinoic acid gene family", Lake Tahoe, CA, USA
- Invited speaker; March Atherosclerosis Forum (MAF), Megève, France
- Invited speaker; European Atherosclerosis society, Munich, Germany
- Invited speaker; European Workshop on Cytokines in Diabetes, Dusseldorf, Germany
- Invited speaker; Japanese-US forum on nutrition, Shirahama, Japan
- Invited speaker; Fondation Léon Frédérique, Liège, Belgique

1997

- Invited speaker; Marabou symposium on Nutrition, Oslo, Norway
- Invited speaker; Hawaii Insulin Resistance meeting, Hawaii, USA
- Invited speaker; Deuel Lipid meeting, Skamania, USA
- Invited speaker; American Chemical Society meeting, San Fransisco, USA
- Invited speaker; European Atherosclerosis Society, Brugge, Belgium
- Invited speaker; Endocrine Society, Minneapolis, USA
- Invited speaker; Aspen Lipid symposium, Aspen, USA

- Invited speaker; International Atherosclerosis Society, Paris, France
- Invited speaker; Biotechnology Symposium: "Nuclear Orphan Receptors, Stockholm, Sweden
- Invited speaker; COSTB5 Symposium on Insulin Resistance, Leiden, Netherlands
- Invited speaker; XI Italian Atherosclerosis Congress, Vibo Valentia, Italia

1998

- Invited speaker; Genetics of NIDDM, Tampere, Finland
- Invited speaker; European Atherosclerosis meeting, Helsinki, Finland
- Invited speaker; Best and Banting Diabetes Center Study day, Toronto
- Invited speaker; The Mediterranean meeting of Biochemistry and Molecular Biology, Marseille, France
- Invited speaker; 69th European Atherosclerosis Society, Helsinki, Finland
- Invited speaker; VIIth International Symposium on Insulin Receptors & Insulin Action, Jerusalem, Israel
- Invited speaker; American Diabetes Association Meeting, Chicago, USA
- Invited speaker; FASEB meeting "Behavioural and Metabolic Sub-phenotypes of Obesities", Snowmass, USA
- Invited speaker; 34th European Association for the Study of Diabetes annual meeting, Barcelona, Spain
- Invited speaker; VIIth European Symposium on Metabolism, Padova, Italy
- Invited speaker; 21st European Lipoprotein Club, Tutzing, Germany
- Invited speaker; 5th IUBMB Conference on the Biochemistry of Health and Diseases, Jerusalem, Israel

1999

- Invited speaker; Xth meeting of the Italian Diabetes Society, Milano, Italy
- Keynote lecturer; Winter meeting of the Finnish Society of Internal Medicine, Helsinki, Finland
- Keynote lecturer; BASO/NASO meeting Maastricht, Holland
- Invited speaker; 5th meeting on Lipoproteins, Enzymes, and Receptors, Hamburg, Germany (invited speaker)
- Invited speaker; Keystone meeting on PPARs, Keystone, USA
- Invited speaker; Endocrine Society meeting, San Diego, USA
- Invited speaker; American Diabetes Association Meeting, San Diego, USA
- Keynote lecturer; Meeting of the German Diabetes Society, Frankfurt, Germany
- Invited speaker; 70th European Atherosclerosis Society meeting, Athens, Greece
- Invited speaker; 9th European Congress on Obesity, Milano, Italy
- Invited speaker; COSTB5 meeting on Signal Transduction, Nice, France
- Invited speaker; Umehara Symposium on Common Diseases, Tokyo, Japan
- Invited speaker; Retinoids 99, Strasbourg, France
- Keynote lecturer; French Endocrine Society, Bordeaux, France
- Invited speaker; Shizuoka Symposium on aging, Shizuoka, Japan
- Keynote address; Japanese Atherosclerosis Society, Osaka, Japan

2000

- Invited speaker; Laragh conference of the American Society of Hypertension, Fort Lauderdale, USA
- Invited speaker; Risk and Prevention, Paris, France
- Invited speaker; German Society of Toxicology, Mainz, Germany
- Invited speaker; 10th European Congress on Obesity, Antwerpen, Belgium
- Keynote lecture: International Atherosclerosis Society, Stockholm, Sweden
- Invited speaker; FEBS lecture course on Transcriptional Regulation, Spetses, Greece
- Invited speaker; 1st meeting on the Clinical Implications of PPAR γ , Boston, USA
- Keynote lecture; International Diabetes Federation, Mexico City, Mexico
- Invited speaker; Biotechnology Symposium "Nuclear receptors in Health and Disease", Stockholm, Sweden

2001

- Invited speaker; Keystone meeting "The PPARs", Keystone, USA
- Prize lecture; 6th Annual Dolan Boyd Pritchett Memorial Lecture, University of Pennsylvania School of Medicine, Philadelphia, USA
- Invited speaker; Diabetes Dialogue, symposium on Insulin Resistance, Geneva, Switzerland
- Invited speaker; 5th European Congress of Endocrinology, Torino, Italy

- Invited speaker; 4th International meeting on Platelets and Vascular Biology, Capri, Italy
- Invited speaker; International Conference on the Biochemistry of Lipids, Bergen, Norway
- Invited speaker; Focus on Diabetes, Erice, Italy
- Keynote lecturer: 12th Meeting of the Argentine Endocrine Society, Buenos Aires, Argentina

2002

- Invited speaker; Keystone meeting "Nuclear receptors", Snowbird, USA
- Invited speaker; Experimental Biology FASEB meeting "Translating the Genome", New Orleans, USA
- Invited speaker and chairman; American Society of Biological Psychiatry et Société Française de Psychiatrie Biologique. "Genomics and mental disease". Paris, France

2003

- Invited speaker; EMBO meeting "Biology of nuclear receptors", Villefranche, France
- Invited speaker; International Atherosclerosis Society, Kyoto, Japan
- Invited speaker; 19th Klenk Symposium "transcriptional regulation of lipid homeostasis", Cologne Germany
- Invited speaker; Nuclear Receptors in Munich, Germany
- Invited speaker; CBATEG symposium on mouse functional genomics, Barcelona, Spain
- Invited speaker; Nobel Conference "Transcriptional control of lipid homeostasis", Stockholm, Sweden
- Invited speaker; Spetsai Summer school "From transcription to physiology" Spetse, Greece
- Organizer and speaker: Stock Conference of the IASO "Adipose tissue; new targets", Lisbon, Portugal
- Invited speaker; Basic research meeting AASLD "NR regulation of hepatobiliary function", Washington, USA

2004

- Organizer and speaker; Keystone meeting "Nuclear receptors; orphan brothers", Keystone, USA
- Invited speaker and chairman; Keystone meeting "Control of Adipogenesis and obesity", Banff, Canada
- EMBO membership lecture; EMBO "Frontiers in Molecular Biology", Vienna, Austria
- Invited speaker; ENDO 2004, New Orleans, USA
- Invited speaker; Mouse mutagenesis meeting, London, UK
- Invited speaker; Code meeting on the metabolic syndrome, Miami, USA
- Invited speaker; 3rd International Nuclear Receptor symposium, Osaka, Japan
- Invited speaker; 6th Insulin action meeting, Kyoto, Japan
- Invited speaker; Days of Molecular Medicine "Integrative physiology and human disease", Cambridge, UK
- Invited speaker; Macophages in inflammation, Toulouse, France
- Morgagni Gold medal Award lecture; Morgagni Symposium, Padova, Italy

2005

- Invited Speaker; Baylor College of Medicine, Houston, USA
- Invited Speaker; Columbia University, New York, USA
- Invited speaker; Cologne Spring Symposium on Molecular Biology, Cologne, Germany
- Invited speaker and chairman; EMBO meeting "Nuclear receptors", Gardone, Italy
- Invited speaker; Osaka, Japan, Japan Adiposcience Meeting
- Organizer; Eumorphia Summer School, Sept 17-23, 2005, Bischenberg, France

2006

- Invited speaker; Deuel Lipid conference, Monterey, USA
- Invited speaker; Keystone meeting "Nuclear receptors; Orphan brothers", Banff, Canada
- Keynote lecture; Japanese Association for the study of Obesity, Kobe, Japan
- Josiah Brown Award Lecture; Josiah Brown Diabetes symposium, UCLA, USA
- Invited lecture; Genomics of Hyperglycemia Symposium, Elsinore, Danmark
- Invited lecture; Cantoblanco Workshop "Molecular biology of obesity and bone remodeling", Madrid, Spain

2007

- Invited speaker; Nature, Salk, IPSEN symposium on "Diseases of Transcription", La Jolla, USA
- Invited speaker; 3rd International Summit on "Cardiometabolic risk", LA, USA

- Invited speaker; 3rd Symposium on aging and caloric restriction, Verbier, Switzerland
- Invited speaker: EPFL, Lausanne, Switzerland
- Keynote lecture; 10th meeting on the "Biology of the NR family", Atlanta, USA
- Invited speaker; Keystone meeting "Nuclear receptors", Steamboat Springs, USA
- Invited speaker; EMBO meeting "Nuclear receptors", Gardone, Italy
- Invited speaker; 1st Bertinoro Systems Biology Workshop, Bertinoro, Italy
- Invited speaker; NIDDK meeting "Nuclear Receptors in Liver and Digestive", Bethesda, USA
- Invited speaker; Brigham and Women's Hospital Cardiovascular and Metabolism seminar series, Boston, USA

2008

- Co-organizer and chairman; EUMODIC annual meeting on "Mouse phenotyping", Bischenberg, France
- Keynote lecture; Baylor College of Medicine, Cell Biology Special Seminar, Houston, USA
- Invited speaker; Keystone meeting "Insulin sensitivity and Diabetes", Breckenridge, USA
- Invited speaker: Frontiers in Biology lecture of the Stanford Genetics Department, Palo Alto, USA
- Keynote lecture; European Association for the Study of the Liver (EASL), Milano, Italy
- Keynote lecture; European Congress of Endocrinology (ECE), Berlin, Germany
- Invited speaker; New York Academy of Science, NY, USA
- Keynote lecture; Shizuoka Symposium on Aging, Shizuoka, Japan
- Invited speaker; CNIO, Madrid, Spain
- Ruysch lecture; Academic Medical Center, Amsterdam, The Netherlands

b. Professional and Educational leadership roles

2003

- Organizer Stock Conference of the International Association for the Study of Obesity "Adipose tissue; new targets", Lisbon, Portugal

2004

- Co-organizer of the Keystone meeting "Nuclear receptors; orphan brothers", Keystone, USA

2005

- Organizer EMBO lecture course and Eumorphia Summerschool "Mouse Models for Human Disease", Bischenberg, France

2008

- Co-organizer EUMODIC annual meeting on "Mouse phenotyping", Bischenberg, France

3. Teaching awards

None

4. Major curriculum offerings

None

E. Report on Clinical activities (between 1988 and 1991)

1. Description of clinical practice:

Field: Endocrinology and Metabolism

Areas of major focus: Intermediary metabolism: lipid & lipoprotein abnormalities, type 2 diabetes, obesity

Sites of practice:

- University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Belgium
- University Hospital, University of Washington, Seattle, USA.

2. Patient Load:

- Two large outpatient consultations per week ~ 160-200 patients total/week. Patients are mainly secondary and tertiary referral cases with obesity, diabetes, and lipid disorders.

- One small outpatient consultation ~ 10 patients/week. Preventive counseling for family members of patients with metabolic and cardiovascular disease.

- Responsible of 10 beds in a University (tertiary) Hospital occupied mainly with diabetes patients, with complications.

3. Clinical contributions

Development of a clinical outpatient unit that counsels life style changes to subjects of families predisposed to metabolic and cardiovascular disease.

PART III: Bibliography

Original articles

1. J. Auwerx, H. Ector and M. Demedts. Sarcoidosis of the heart: a study of 5 patients. Acta Clin. Belg. 1983, 38, 302-308.
2. R. Bouillon, J. Auwerx, L. Dekeyser, W. Lissens and P. De Moor. Serum vitamin D metabolites and their binding proteins in patients with liver cirrhosis. J. Clin. Endocr. Metab. 1984, 59, 86-89.
3. J. Auwerx, M. Demedts and R. Bouillon. Altered parathyroid setpoint to calcium in the syndrome of familial hypocalciuric hypercalcemia. Acta Endocrinol. 1984, 106, 215-218.
4. J. Auwerx, M. Demedts, R. Bouillon and J. Desmet. Coexistence of idiopathic pulmonary fibrosis and hypocalciuric hypercalcemia in a family; a cross sectional study. Eur. J. Clin. Invest. ,1985, 15, 6-14.
5. M. Demedts, J. Auwerx, P. Godderis, R. Bouillon, A. Gyselen and J. Lauweryns. The inherited association of interstitial lung disease, hypocalciuric hypercalcemia and defective granulocyte function. Am. Rev. Resp. Disease, 1985, 131, 470-475.
6. J. Auwerx, M. Boogaerts, J.L. Ceuppens and M. Demedts. Defective host defense mechanisms in a family with hypocalciuric hypercalcemia and coexistent interstitial lung disease. Clin. Exper. Immunol., 1985, 62, 57-64.
7. R. Bouillon, J. Auwerx. Hypercalcemia: increasing diagnostic possibilities to cope with an increasing list of etiologies. Acta Clin. Belg., 1985, 40, 215-219.
8. B. Gheysens, J. Auwerx, A. Van den Eeckhout and M. Demedts. Cobalt induced asthma in diamond polishers. Chest, 1985, 82, 740-744.
9. B.L. Nyomba, J. Auwerx, T.L. Peeters, W. Pelemans, J. Reynaert, R. Bouillon, G. Vantrappen and P. De Moor. Pancreatic secretion in men with subclinical vitamin D deficiency. Diabetologia, 1986, 29, 34-38.
10. J. Auwerx, L. Dekeyser and R. Bouillon. Decreased free 1,25-dihydroxyvitamin D₃ index in patients with the nephrotic syndrome. Nephron, 1986, 42, 231-235.
11. R. Bouillon, J. Auwerx, W. Lissens, W. Pelemans. Vitamin D status in the elderly: seasonal substrate deficiency causes 1,25-dihydroxycholecalciferol deficiency. Am. J. Clin. Nutr., 1987, 45, 755-763.
12. J. Auwerx, J. Dequeker, R. Bouillon, P. Geussens, J. Nijs. Effects of diabetes mellitus on hormonal control of mineral metabolism and on bone mass at the peripheral and axial skeleton. Diabetes, 1988, 37, 8-12.
13. J. Auwerx, R. Bouillon, D. Collen. Tissue plasminogen activator and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis, 1988, 8, 68-72.
14. J. Auwerx, S. Deeb, J. Brunzell, R. Peng, A. Chait . Transcriptional activation of the lipoprotein lipase and apolipoprotein E genes accompanies differentiation in some human macrophage-like cell lines. Biochemistry, 1988, 27, 2651-2657.
15. B. Staels, J. Auwerx, L. Chan, A. van Tol, M. Rosseneu, G. Verhoeven. Influence of development, estrogens, and food intake on apolipoprotein A-I, A-II and E mRNA in rat liver. J. Lipid Res. 1989, 30, 1137-1147.
16. J. Auwerx, S. Deeb, A. Chait. Transcriptional regulation of the LDL receptor and HMG-CoA reductase genes in THP-1 cells by protein kinase C and a labile negative regulatory protein. Proc. Natl. Acad. Sci. USA, 1989, 86, 1133-1137.
17. J. Auwerx, S. Deeb, J. Brunzell, A. Chait. Regulation of the LPL gene in THP-1 cells. Biochemistry, 1989, 28, 4563-4567.
18. J. Auwerx, A. Chait, G. Wolfbauer, S.S. Deeb. Involvement of Second Messengers in regulation of the low density lipoprotein receptor gene. Mol. Cell. Biol., 1989, 9, 2298-2302.
19. J. Auwerx, C. Marzetta, J. Hokanson, J. Brunzell. Relationship between hepatic triglyceride lipase and low density lipoprotein characteristics. Arteriosclerosis, 1989, 9, 319-325.
20. J. Auwerx, A. Chait, G. Wolfbauer, S.S. Deeb. Loss of copper-zinc superoxide dismutase gene expression in differentiated cells of myelo-monocytic origin. Blood 1989 74, 1807-1810.
21. J. Auwerx, S. Babirak, W. Fujimoto, P.-H. Iverius, J. Brunzell. Protein defects in lipoprotein lipase

- deficiency Eur. J. Clin. Invest. 1989, 19, 433-437.
22. J. Auwerx, S. P. Babirak, G. Stahnke, H. Will, S.S. Deeb, J. Hokanson, J. Brunzell. Coexistence of abnormalities of hepatic lipase and lipoprotein lipase in a large family. Am. J. Hum. Genet. 1990, 46, 470-477.
 23. B. Staels, H. Jansens, G. Stahnke, H. Van Tol, H. Will, G. Verhoeven, J. Auwerx. Development, food intake, and ethinylestradiol influence hepatic triglyceride lipase and low density lipoprotein receptor mRNA levels in rats. J. Lip. Res. 1990, 31, 1211-1218.
 24. B. Staels, A. Van Tol, G. Verhoeven, J. Auwerx. Apolipoprotein AIV messenger ribonucleic acid abundance is regulated in a tissue specific manner. Endocrinology 1990, 126, 2153-2163.
 25. J. Auwerx, B. Staels, P. Sassone-Corsi. Coupled and uncoupled induction of *fos* and *jun* mRNA transcription by second messengers in cells of hematopoietic origin. Nucl. Acids Res. 1990, 18, 221-228.
 26. J. R. Naranjo, B. Mellstrom, J. Auwerx, F. Mollinedo, P. Sassone-Corsi. Unusual c-fos induction upon chromaffin PC12 differentiation by sodium butyrate: loss of fos autoregulatory function. Nucl. Acids Res. 1990, 18, 3605-3610.
 27. B. Staels, A. van Tol, H. Will, G. Verhoeven, J. Auwerx. Alterations in thyroid hormone status modulate apolipoproteins, hepatic triglyceride lipase, and low density receptor levels in rats. Endocrinology 1990, 127, 1144-1152.
 28. J. Auwerx, P. Sassone-Corsi. IP-1: a dominant inhibitor of fos/jun whose activity is modulated by phosphorylation. Cell 1991, 64, 983-993.
 29. B. Staels, A. van Tol, G. Verhoeven, J. Auwerx. Variable effects of different corticosteroids on plasma lipids, apolipoproteins, and hepatic apolipoprotein mRNA levels in rats. Arteriosclerosis and Thrombosis 1991, 11, 760-769.
 30. R. Degroot, J. Auwerx, M. Karperien, B. Staels, W. Kruyer. Activation of jun B by PKC and PKA signal transduction through a novel cis-acting element. Nucl. Acids Res. 1991, 19, 775-781.
 31. M. Van Ranst, K. Norga, S. Masure, P. Proost, F. Vandekerckhove, J. Auwerx, J. Van Damme, G. Opendakker. The cytokine-protease connection: identification of a 96 kDa THP-1 gelatinase and regulation by interleukin-1 and cytokine inducers. Cytokine 1991, 3, 231-239.
 32. B. Staels, A. van Tol, H. Jansen, J. Auwerx. The effects of probucol on lipoprotein metabolism in the rat. Biochim. Biophys. Acta 1991, 1085, 131-135.
 33. P. Demacker, B. Staels, A. Stalenhoef, J. Auwerx. Increased removal of beta-very low density lipoproteins after ethinyl estradiol is associated with increased mRNA levels for hepatic lipase, lipoprotein lipase, and the low density lipoprotein receptor in watanabe heritable hyperlipidemic rabbits. Arteriosclerosis and Thrombosis 1991, 11, 1652-1659.
 34. J. Auwerx, B. Staels, F. Van Vaeck, G. Verhoeven, and J. Ceuppens. IgG Fc receptor expression during macrophage differentiation of the monocytic leukemia cell line, THP-1. Leukemia Research 1992, 16, 317-328.
 35. B. Staels, A. van Tol, T. Andreu, J. Auwerx. Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissue-selective manner in the rat. Arteriosclerosis and Thrombosis 1992, 12, 286-294.
 36. B. Staels, J. Peinado-Onsurbe, J. Auwerx. Down-regulation of hepatic lipase gene expression and activity by fenofibrate. Biochim. Biophys. Acta 1992, 1123, 227-230.
 37. K. Descheemaeker, S. Wijns, L. Nelles, J. Auwerx, T. Ny, D. Collen. Interaction of AP-1, AP-2, and Sp-1-like proteins with two distinct sites in the upstream regulatory region of the plasminogen activator inhibitor-1 gene mediates the phorbol, 12-myristate, 13-acetate response. J. Biol. Chem. 1992, 267, 15086-15091.
 38. B. Staels, A. van Tol, G. Skretting, J. Auwerx. Lecithin:cholesterol acyltransferase gene expression is regulated in a tissue-selective manner by fibrates; Lack of regulation by other hypolipidemic drugs and hormones. J. Lipid Res. 1992, 33, 727-735.
 39. J. Auwerx, P. Sassone-Corsi. Regulation of AP-1 and IP-1 by signal transduction pathways and cell growth. Oncogene 1992, 7, 2271-2280.
 40. B. Staels, J. Auwerx. Perturbation of developmental gene expression in rat liver by fibric acid derivatives: lipoprotein lipase and alfa-fetoprotein as models. Development 1992, 115, 1035-1044.
 41. J. Peinado-Onsurbe, B. Staels, S. Deeb, J. Auwerx. Lipoprotein lipase expression in undifferentiated

- hepatoma cells is regulated by progesterone and protein kinase A. Biochemistry 1992, 31, 10121-10128.
42. J. Peinado-Onsurbe, B. Staels, S. Deeb, I. Ramirez, M. Llobera, J. Auwerx. Neonatal extinction of liver lipoprotein lipase expression. Biochim. Biophys. Acta 1992, 1131,281-286.
 43. J. Auwerx, R. Bouillon, H. Kesteloot. Relation between 25-hydroxyvitamin D3, apolipoprotein A-I, and high density lipoprotein cholesterol. Arteriosclerosis and Thrombosis 1992, 12, 671-674.
 44. R. de Groot, J. Auwerx, M. Bourouis, P. Sassone-Corsi. Negative regulation of jun/AP-1 by glycogen synthase kinase 3 and the drosophila kinase shaggy. Oncogene 1992, 8, 841-847.
 45. H. Jansen, A van Tol, J. Auwerx, G. Skretting, B. Staels. Opposite regulation of hepatic lipase and lecithin: cholesterol acyltransferase by glucocorticoids in rats. Biochim. Biophys. Acta 1992, 1128, 181-185.
 46. K. Schoonjans, B. Staels, P. Grimaldi, J. Auwerx. Acyl CoA Synthetase mRNA expression is controlled by fibric derivatives, feeding, and liver proliferation. Eur J. Biochem. 1993, 216, 615-622.
 47. P. Van Dijck, K. Schoonjans, P. Sassone-Corsi, J. Auwerx, G. Verhoeven. A fos-jun element in the first intron of an alfa-2u-globulin gene. Mol. Cell. Biochem. 1993, 125, 127-136.
 48. J. Peinado-Onsurbe, B. Staels, Vanderschueren D., Bouillon R., Auwerx J. The effects of sex steroids on hepatic and lipoprotein lipase activity and mRNA in the rat. Hormone Research 1993, 40,184-188.
 49. 1993-5. K. Schoonjans, B. Staels, P. Devos, J. Szpirer, C. Szpirer, S. Deeb, G. Verhoeven, and J. Auwerx. Developmental extinction of liver lipoprotein lipase mRNA expression might be regulated by an NF-1 like site. FEBS letters 1993, 329, 89-95
 50. T. Lemberger, B. Staels, R. Saladin, B. Desvergne, J. Auwerx, W. Wahli. Regulation of the Peroxisome Proliferator Activated Receptor γ gene by glucocorticoids. J. Biol. Chem. 1994, 269, 24527-24530.
 51. N. Vu-Dac, K. Schoonjans, B. Laine, J.C. Fruchart, J. Auwerx, B. Staels. Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the Peroxisome Proliferator Activated Receptor with its response element. J. Biol. Chem. 1994, 269, 31012-31018.
 52. G.P. Jarvik, M. Austin, J. Selby, R. Fabsitz, J. Auwerx, T. Reed, J. Christian, S. Deeb. Genetic influences on age-related change in total cholesterol and LDL cholesterol and triglyceride levels: longitudinal apo E genotype effects. Genet. Epidemiology 1994, 11, 375-384.
 53. T. Reed, D. Carmelli, G. Swan, J.C.S. Breitner, K. Welsh, G.P. Jarvik, S. Deeb, J. Auwerx. Lower cognitive performance in normal older male twins carrying the apolipoprotein E4 allele. Arch. Neurol. 1994, 51, 1189-1192.
 54. B. Staels, N. Vu-Dac, V.A. Kosykh, R. Saladin, J.C. Fruchart, J. Dallongeville, J. Auwerx. Fibrates down-regulate apolipoprotein C-III expression independent of the induction of peroxisomal acyl co-enzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J. Clin. Invest. 1995, 95,705-712.
 55. R. Busca, M. Pujana, P. Pognonec, J. Auwerx, S.S. Deeb, M. Reina, S. Vilaro. Absence of N-glycosylation at asparagine 43 in human lipoprotein lipase induces its accumulation in the rough endoplasmic reticulum and alters this cellular compartment. J. Lipid Res. 1995, 36, 939-951.
 56. R. Busca, J. Peinado, E. Vilella, J. Auwerx, S. Deeb, S. Deeb, S. Vilaro, M. Reina. The mutant asn291-->ser human lipoprotein lipase is associated with reduced catalytic activity and does not influence binding to heparin. FEBS letters 1995, 367, 257-262.
 57. R. Saladin, P. De Vos, M. Guerre-Millo, A. Leturque, J. Girard, B. Staels, J. Auwerx. Transient increase in obese gene expression after food intake and insulin. Nature, 1995, 377, 527-529
 58. C. Aperlo, P. Pognonec, R. Saladin, J. Auwerx, K. Boulukos. cDNA cloning and characterization of the transcriptional activities of hamster peroxisomal proliferated receptor, haPPAR γ . Gene 1995, 162, 297-302.
 59. P. DeVos, R. Saladin, J. Auwerx, B. Staels. Induction of ob gene expression by corticosteroids is accompanied by body weight loss and reduced food intake. J. Biol. Chem. 1995, 270, 15958-15961.
 60. A. Mehlum, B. Staels, N. Duverger, A. Tailleux, G. Castro, C. Fievet, G. Luc, J.C. Fruchart, G. Olivecrona, G. Skretting, J. Auwerx, H. Prydz. Tissue specific expression of the human LCAT gene

- in transgenic mice alters blood lipids, lipoproteins and lipases towards a less atherogenic profile. Eur. J. Biochem. 1995, 230, 567-575.
61. N. Vu-Dac, K. Schoonjans, V. Kosykh, J. Dallongeville, J.C. Fruchart, B. Staels, J. Auwerx. Fibrates increase apolipoprotein A-II expression through the peroxisome proliferator activated receptor. J. Clin. Invest. 1995, 96, 741-750.
 62. S. Geffroy, P. DeVos, B. Staels, B. Duban, J. Auwerx, B. de Martinville. Localization of the human ob gene to chromosome 7q32 by fluorescence in situ hybridization. Genomics 1995, 28, 603-604.
 63. K. Schoonjans, M. Watanabe, H. Suzuki, A. Mahfoudi, G. Krey, W. Wahli, T. Yamamoto, P. Grimaldi, W. Wahli, J. Auwerx. Induction of acyl-Coenzyme A synthetase gene expression by fibrates is mediated by a PPAR-responsive element in the 1C promoter. J. Biol. Chem. 1995, 270, 19269-19276.
 64. L. Berthou, R. Saladin, P. Yaqoob, D. Branellec, P. Calder, J.C. Fruchart, P. Deneffe, J. Auwerx, B. Staels. Regulation of rat apolipoprotein A-I, apolipoprotein A-II and acyl-coenzyme A gene expression by fibrates and dietary fatty acids. Eur. J. Biochem. 1995, 232, 179-187.
 65. T. Lemberger, R. Saladin, M. Vazquez, F. Assimacopoulos, B. Staels, B. Desvergne, W. Wahli, J. Auwerx. Expression of the peroxisome proliferator activated receptor γ gene is stimulated by stress and follows a diurnal rhythm. J. Biol. Chem. 1996, 271, 1764-1769.
 66. R. Busca, M. Martinez, E. Vilella, P. Pognonec, J. Auwerx, M. Reina, S. Vilaro. The mutation Gly 142 \rightarrow Glu in human lipoprotein lipase produces a missorted protein that is diverted to lysosomes. J. Biol. Chem. 1996, 271, 2139-2146.
 67. L. Berthou, N. Duverger, F. Emmanuel, S. Langouet, J. Auwerx, A. Guillouzo, J.C. Fruchart, E. Rubin, P. Deneffe, B. Staels, D. Branellec. Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apo A-I transgenic mice. J. Clin Invest. 1996, 97, 2408-2416.
 68. J. Auwerx, K. Schoonjans, J.C. Fruchart, B. Staels. Transcriptional control of triglyceride metabolism: fibrates change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR. Atherosclerosis 1996, 124, S29-S37.
 69. R. Casaroli Marano, J. Peinado Onsurbe, M. Reina, B. Staels, J. Auwerx, S. Vilaro. Lipoprotein lipase in highly vascularized structures of the eye. J. Lipid Res. 1996, 37, 1037-1044.
 70. N. Vu-Dac, K. Schoonjans, V. Kosykh, J. Dallongeville, B. Staels, J. Auwerx. Retinoids increase human apolipoprotein A-II expression through activation of the retinoid X receptor but not the retinoic acid receptor. Mol. Cell. Biol. 1996, 16, 3350-3360.
 71. S.G. Miller, P. DeVos, M. Guerre-Millo, K. Wong, T. Hermann, B. Staels, M.R. Briggs, J. Auwerx. The adipocyte specific transcription factor C/EBP α modulates human ob gene expression. Proc. Natl. Acad. Sci. USA 1996, 93, 5507-5511.
 72. B. Staels, G. Martin, M. Martinez, C. Albert, J. Peinado-Onsurbe, R. Saladin, D. W. Hum, M. Reina, S. Vilaro, J. Auwerx. Expression and regulation of the lipoprotein lipase gene in human adrenal cortex. J. Biol. Chem. 1996, 271, 17425-17432.
 73. P. De Vos, S. Miller, A. Lefebvre, M. Guerre-Millo, K. Wong, R. Saladin, L. Hamann, B. Staels, M. R. Briggs, J. Auwerx. The expression of the human ob gene is decreased by activation of PPAR γ , but not PPAR α , via a direct effect on its promoter. J. Clin Invest. 1996, 98, 1004-1009.
 74. J.P. Bossu, F.L. Chartier, J.C. Fruchart, J. Auwerx, B. Staels, B. Laine. Two regulatory elements of similar structure and placed in tandem account for the repressive activity of the first intron of the human apolipoprotein A-II gene. Biochem. J. 1996, 318, 547-553.
 75. H. Vidal, D. Auboeuf, P. De Vos, B. Staels, J.P. Riou, J. Auwerx, M. Laville. The expression of ob gene is not acutely regulated by insulin and fasting in human subcutaneous adipose tissue. J. Clin. Invest. 1996, 98, 251-255.
 76. K. Schoonjans, J. Peinado-Onsurbe, A.-M. Lefebvre, R. A. Heyman, M. Briggs, S. Deeb, B. Staels, J. Auwerx. PPAR α and PPAR γ activators direct a distinct transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 1996, 15, 5336-5348.
 77. R. Saladin, N. Vu-Dac, J.C. Fruchart, J. Auwerx, B. Staels. Transcriptional induction of rat liver apolipoprotein A-I gene expression by glucocorticoids requires the glucocorticoid receptor and a labile cell-specific protein. Eur. J. Biochem. 1996, 239, 451-459.
 78. R. Sabugal, M.Q. Robert, J. Julve, J. Auwerx, M. Llobera, J. Peinado-Onsurbe. Hepatic regeneration induces changes in lipoprotein lipase activity in several tissues and its re-expression in liver.

- Biochem. J. 1996, 318,597-602.
79. G. Jarvik, E. Goode, M. Austin, J. Auwerx, S. Deeb, G. Schellenberg, T. Reed. Evidence that the apolipoprotein E-genotype effects on lipid levels can change with age in males: a longitudinal analysis. Am. J. Hum. Genet., 1997, 61, 171-181
 80. D. Auboeuf, J. Rieusset, L. Fajas, P. Vallier, V. Frering, J.P. Riou, M. Laville, B. Staels, J. Auwerx, H. Vidal. Tissue distribution and quantification of the expression of PPARs and LXR α in humans: no alterations in adipose tissue of obese and NIDDM patients. Diabetes, 1997, 48, 1319-1327.
 81. G. Martin, K. Schoonjans, B. Staels, J. Auwerx. Coordinate regulation of the fatty acid transport protein (FATP) and Acyl CoA Synthetase (ACS) genes by PPAR α and PPAR γ activators. J. Biol. Chem., 1997, 272, 28210-28217.
 82. L. Fajas, D. Auboeuf, E. Raspé, K. Schoonjans, A. Lefebvre, J. Najib, R. Saladin, M. Laville, JC Fruchart, S. Deed, A. Puig-Vidal, J. Flier, MR Briggs, B. Staels, H. Vidal, J. Auwerx. The human PPAR γ gene: organization, promoter analyzis, and expression. J. Biol. Chem., 1997, 272, 18779-18789.
 83. J. Peters, N. Hennuyer, B. Staels, J.C. Fruchart, C. Fievet, F. Gonzalez, J. Auwerx. Alterations in lipoprotein metabolism in PPAR α -deficient mice. J. Biol. Chem., 1997, 272,27307-27312.
 84. L. Froyland, L. Madsen, H. Vaagenes, G.K. Totland, J. Auwerx, H. Kryvi, B. Staels, R. Berge. The mitochondrion is the principle target for nutritional and pharmacological control of triglyceride metabolism. J. Lipid. Res., 1997, 38, 1851-1858.
 85. L. Fajas, B. Staels, J. Auwerx. A new method for cycle sequencing on large DNA templates. Biotechniques, 1997,23, 1034-1036.
 86. S. Hallakou, L. Doare, F. Fougelle, M. Kergoat, M. Guerre-Millo, M.F. Berthault, I. Dugail, J. Morin, J. Auwerx, P. Ferré. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes, 1997, 46,1393-1399.
 87. A. Lefebvre, J. Peinado-Onsurbe, I. Leitersdorf, M.R. Briggs, J.R. Paterniti, J.C. Fruchart, C. Fievet, J. Auwerx, B. Staels. Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates. Arterioscler. Thromb. Vasc. Biol., 1997, 17, 1756-1764.
 88. J. Dallongeville, C. Le Fur, P. Lebel, J.L. Edmé, B. Hecquet, J.C. Fruchart, J. Auwerx, M. Romon. The increase in serum leptin levels after food intake is correlated with insulin levels in normal subjects. Int. J. Obesity, 1998, 22, 728-733
 89. A. Lefebvre, M. Laville, N. Vega, J.P. Riou, L. Van Gaal, J. Auwerx, H. Vidal. Depot-specific differences in adipose tissue gene expression in lean and obese subjects. Diabetes, 1998, 47, 98-103.
 90. A. Meirhaeghe, L. Fajas, N. Hellebecque, D. Cottel, P. Lebel, J. Dallongeville, S. Deeb, J. Auwerx, P. Amouyel. A genetic polymorphism of the peroxisome proliferator-activated receptor γ gene influences plasma leptin levels in obese humans. Hum. Mol. Genet., 1998, 7, 435-440.
 91. C. Vigouroux, L. Fajas, E. Khallouf, M. Meier, G. Gyapay, J. Auwerx, J. Weissenbach, J. Capeau, J. Magré. Human peroxisome proliferator-activated receptor gamma 2: genetic mapping, identification of a variant in the coding sequence, and exclusion as the gene responsible for lipoatrophic diabetes. Diabetes, 1998, 47,490-492
 92. J. Lepercq, M. Cauzac, N. Lahlou, J. Girard, J. Auwerx, S. Haugel-de Mouzon. Overexpression of placental leptin in diabetic pregnancy: a critical role for insulin. Diabetes, 1998, 47, 847-850
 93. P. DeVos, A. Lefebvre, I. Shribo, J.C. Fruchart, J. Auwerx. Glucocorticoids induce the expression of the leptin gene through a non-classical mechanism of transcriptional activation. Eur. J. Biochem. 1998, 253, 619-626.
 94. M. Ricote, J. Huang, L. Fajas, J. Najib, A. Li, J. Welch, J. Witztum, J. Auwerx, W. Palinski, C. K. Glass. Expression of the peroxisome proliferator-activated receptor γ in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized LDL. Proc. Natl. Acad. Sci USA 1998, 95, 7614-7619
 95. R. Busca, M. Martinez, E. Villela, J. Peinado, J.L. Gelpi, S. Deeb, J. Auwerx, M. Reina, S. Vilaro. The carboxy-terminal region of human lipoprotein lipase is necessary for its exit from the endoplasmic reticulum. J. Lipid Res. 1998, 39, 821-833.
 96. A. Lefebvre, I. Chen, P. Desreumaux, J. Najib, J.C. Fruchart, K. Geboes, M. Briggs, R. Heyman, J.

- Auwerx. Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57Bl/6J-APCMin $+/+$ mice. Nature Medicine, 1998, 4, 1053-1057.
97. L. Fajas, J.C. Fruchart, J. Auwerx. PPAR γ 3 mRNA: a distinct PPAR γ mRNA subtype transcribed from an independent promoter. FEBS letters, 1998, 438, 55-60 .
 98. S.S. Deeb, L. Fajas, M. Nemoto, M. Laakso, W. Fujimoto, J. Auwerx. A Pro12Ala substitution in the human peroxisome proliferator activated receptor gamma 2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nature Genetics, 1998, 20, 284-287.
 99. J Rieusset, F. Andreelli, D. Auboeuf, M. Roques, P. Vallier, J-P. Riou, J. Auwerx, M. Laville and H. Vidal. Insulin acutely regulates the expression of the peroxisome proliferator-activated receptor γ in human adipocytes. Diabetes, 1999, 48,699-705.
 100. R. Saladin, L. Fajas, S. Dana, Y.D. Halvorsen, J. Auwerx, M. Briggs. Differential regulation of peroxisome proliferator gamma1 (PPARgamma1) and PPARgamma2 mRNA expression in early stages of adipogenesis. Cell Growth Differ. 1999, 10, 43-48.
 101. L. Fajas, K. Schoonjans, L. Gelman, J.B. Kim, J. Najib, J.-C. Fruchart, M. Briggs, B.M. Spiegelman, J. Auwerx Regulation of PPAR γ expression by ADD-1/SREBP: implications for adipocyte differentiation and metabolism. Mol. Cell. Biol. 1999, 19, 5495-5503.
 102. 1999-7. K. Schoonjans, J. Peinado-Onsurbe, J-C Fruchart, A. Tailleux, C. Fievet, J. Auwerx. HMG-CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C-III and lipoprotein lipase. FEBS letters 1999, 452, 160-164
 103. J. Ek, S.A. Urhammer, T.I.A. Sorensen, T. Andersen, J. Auwerx, O. Pedersen. Homozygosity of the Pro12Ala variant of the peroxisome proliferator-activated receptor γ 2 (PPAR γ 2): divergent modulating effects on body mass index in obese and lean men of Caucasian origin. Diabetologia 1999, 42, 892-895
 104. P. Desreumaux,, O. Ernst, K. Geboes, L. Gambiez, D. Berrebi, H. Muller-Alouf, S. Hafraoui, D. Emilie, N. Ectors, M. Pechmaur, A. Cortot, M. Capron, J. Auwerx, J.F. Colombel. Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. Gastroenterology, 1999, 117, 73-81
 105. L. Gelman, G. Zhou, L. Fajas, E. Raspe, JC Fruchart, J. Auwerx. p300 interacts with the N- and C-terminal part of PPAR γ 2 in a ligand-independent and -dependent manner, respectively. J. Biol. Chem. 1999, 274, 7681-7688.
 106. A. Lefebvre, B. Paulweber, L. Fajas, J. Woods, C. McCrary, J.F. Colombel, J. Najib, J.C. Fruchart, C. Datz, H. Vidal, P. Desreumaux, J. Auwerx. Peroxisome proliferator-activated receptor gamma is induced during differentiation of colon epithelium. J. Endocrinol. 1999, 162, 331-340
 107. 1999-14. R. Valve, K. Sivenius, R. Miettinen, J. Pihlajamaki, A. Rissanen, S.S. Deeb, J. Auwerx, M. Uusitupa, M. Laakso. Two polymorphisms in the peroxisome proliferator-activated receptor gamma gene are associated with severe overweight among obese woman. J. Clin. Endocrinol. Metab. 1999, 84, 3708-3712.
 108. J. Rieusset, J Auwerx, H. Vidal. Regulation of gene expression by activation of the peroxisome-proliferator activated receptor gamma with rosiglitazone in human adipocytes. Biochem. Biophys. Res. Commun. 1999, 265, 265-271
 109. K. Hanley, L.G. Komuves, D.C. Ng, K. Schoonjans, S.S. He, P. Lau, D.D. Bikle, M.L. Williams, P.E. Elias, J. Auwerx, K.R. Feingold. Farnesol increases differentiation in epidermal keratinocytes in vitro and in vivo via PPAR α . J. Biol. Chem. 2000, 275,11484-11491.
 110. K.A. Tobin, H.Hermansen Steineger, S. Alberti, O. Spydevold, J. Auwerx, J.-A. Gustafsson, H. I. Nebb. Cross-talk between fatty acid and cholesterol metabolism mediated by LXR α . Mol. Endocrinol. 2000, 14,741-752
 111. G. Martin, H. Poirier, N. Hennuyer, D. Crombie, J.C. Fruchart, R. Heyman, P. Besnard, J. Auwerx. Induction of fatty acid transport protein 1 and acyl-CoA synthase genes by dimer selective rexinoids suggests that the PPAR-RXR heterodimer is their molecular target. J. Biol. Chem. 2000, 275, 12612-12618
 112. A. Meirhaeghe, L. Fajas, N. Helbecque, D. Cotel, J. Auwerx, S.S. Deeb, P. Amouyel. Impact of the peroxisome proliferator activated receptor gamma2 Pro12Ala mutation on adiposity, lipids and non-insulin dependent diabetes mellitus. Int. J. Obes. Relat. Metab. Disord. 2000, 24, 195-199
 113. A Meirhaeghe, G. Martin, M. Nemoto, S. Deeb, D. Cotel, J. Auwerx, P. Amouyel, N. Helbecque. Intronic polymorphism in the fatty acid transport protein 1 gene is associated with increased plasma

- triglyceride levels in a French population. Arterioscler. Thromb. Vasc. Biol. 2000, 20, 1330-1334.
114. G. Martin, M. Nemoto, L. Gelman, S. Geffroy, J. Najib, J. Fruchart, P. Roevens, B. de Martinville, S. Deeb, J. Auwerx. The Human Fatty Acid Transport Protein-1 (SLC27A1; FATP-1) cDNA and Gene: Organization, Chromosomal Localization, and Expression. Genomics. 2000, 66, 296-304.
 115. M. D. Leibowitz, C. Fievet, N. Hennuyer, J. Peinado-Onsurbe, H. Duez, J. Berger, C.A. Cullinan, C.P. Sparrow, J. Baffic, G.D. Berger, C. Santini, R.W. Marquis, R.L. Tolman, R.G. Smith, D.E. Moller, J. Auwerx. Activation of PPAR δ alters lipid metabolism in db/db mice. FEBS letters, 2000, 473, 333-336.
 116. T. T. Lu, M. Nakishima, J.J. Repa, K. Schoonjans, T. A. Kerr, J. Auwerx, D.J. Mangelsdorf. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol. Cell 2000, 6, 507-515.
 117. K. Schoonjans, L. Gelman, C. Haby, M. Briggs, J. Auwerx. Induction of LPL gene expression by sterols is mediated by a sterol regulatory element and independent of the presence of multiple E boxes. J. Mol. Biol. 2000, 304, 323-334.
 118. C. Binnert, H.A. Koistinen, G. Martin, F. Andreelli, P. Ebeling, V.A. Koivisto, M. Laville, J. Auwerx, H. Vidal. Fatty transport protein-1 mRNA expression in skeletal muscle and in adipose tissue in humans. Am. J. Physiol. (Endocrinol. & Metabol.) 2000, 279, E1072-1079.
 119. M. Dubois, F. Pattou, J. Kerr-Conte, V. Gmyr, B. Vandewalle, P. Desreumaux, J. Auwerx, K. Schoonjans, J. Lefebvre. Expression of peroxisome proliferator-activated receptor gamma in normal human pancreatic islet cells. Diabetologia 2000, 43, 1165-1169.
 120. L.G. Komuves, K. Hanley, A.M. Lefebvre, M.Q. Man, D.C. Ng, D.D. Bikle, M.L. Williams, P.M. Elias, J. Auwerx, K.R. Feingold. Stimulation of PPARalpha promotes epidermal keratinocyte differentiation *in vivo*. J. Invest. Dermatol. 2000, 115, 353-360.
 121. J. Pihlajamaki, R. Miettinen, R. Valve, L. Karjalainen, L. Mykkanen, J. Kuusisto, S. Deeb, J. Auwerx, M. Laakso. The Pro12Ala substitution in the peroxisome proliferator activated receptor gamma 2 gene is associated with an insulin-sensitive phenotype in families with combined hyperlipidemia and in nondiabetic elderly subjects with dyslipidemia. Atherosclerosis 2000, 151, 567-574.
 122. J. Rieusset, C. Chambrier, K. Bouzakri, E. Dusserre, J. Auwerx, J-P Riou, M. Laville and H. Vidal. The Expression of the p85 alpha Subunit of Phosphatidylinositol 3-Kinase is Induced by Activation of the Peroxisome Proliferator-Activated Receptor gamma in Human Adipocytes: Possible Role in the Insulin Sensitizing Effect of the Thiazolidinediones. Diabetologia 2001, 44,544-554.
 123. T. Claudel, M.D. Leibowitz, C. Fievet, A. Tailleux, B. Wagner, J.J. Repa, G. Torpier, J.M. Lobaccaro, J.R. Paterniti, D. J. Mangelsdorf, R. A. Heyman, J. Auwerx. Reduction of atherosclerosis in apolipoprotein E knock-out mice by activation of the retinoid X receptor. Proc. Natl. Acad. Sci. USA 2001, 98,2610-2615.
 124. P.J.A. Davies, S.A. Berry, G.L. Shipley, R.H. Eckel, N. Hennuyer, D.L. Crombie, K.M. Ogilvie, J. Peinado-Onsurbe, C. Fievet, M.D. Leibowitz, R. A. Heyman, J. Auwerx. Metabolic effects of rexinoids: tissue-specific regulation of lipoprotein lipase activity. Mol. Pharmacol. 2001, 59, 170-176
 125. P. Desreumaux, L. Dubuquoy, S. Nutten, M. Pechmaur, W. Englaro, K. Schoonjans, B. Derijard, B. Desvergnés, W. Wahli, P. Chambon, M.D. Leibowitz, J-F. Colombel, J. Auwerx. Attenuation of colon inflammation through the RXR / PPAR γ heterodimer: a basis for new therapeutic strategies. J. Exp. Med. 2001, 193, 827-838.
 126. A. Tarrade, K. Schoonjans, L. Pavan, J. Auwerx, C. Rochette-Egly, D. Evain-Brion, T. Fournier. PPARgamma / RXRalpha heterodimers control human trophoblast invasion. J. Clin. Endocrinol. Metab. 2001, 86, 5017-5024.
 127. A. Tarrade, K. Schoonjans, J. Guibourdenche, J.M. Bidart, M. Vidaud, J. Auwerx, C. Rochette-Egly, D. Evain-Brion. PPARgamma / RXRalpha heterodimers are involved in human cgbeta synthesis and human trophoblast differentiation. Endocrinology 2001, 142, 4504-4514.
 128. T.E. Akiyama, C.J. Nicol, C. Fievet, B. Staels, J.M. Ward, J. Auwerx, S.S. Lee, F.J. Gonzalez, J.M. Peters. Peroxisome proliferator-activated receptor alpha regulates lipid homeostasis, but is not associated with obesity; studies with congenic mouse lines. J. Biol. Chem. 2001, 276, 39088-39093.
 129. S. Rocchi, F. Picard, J. Vamecq, L. Gelman, N. Potier, D. Zeyer, L. Dubuquoy, P. Bac, M.F. Champy, K.D. Plunket, L.M. Leesnitzer, S.G. Blanchard, P. Desreumaux, D. Moras, J.P. Renaud, J. Auwerx. A Unique PPAR γ ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol.

- Cell 2001, 8, 737-747.
130. M.Y. Sheu, A.J. Fowler, J. Kao, M. Smuth, K. Schoonjans, J. Auwerx, J.W. Fluhr, M.Q. Man, P.M. Elias, K.R. Feingold. Topical peroxisome proliferator activated receptor alpha activators reduce inflammation in irritant and allergic contact dermatitis models. J. Invest. Dermatol. 2002, 118, 94-101.
 131. C. Brendel, L. Gelman, J. Auwerx. Multiprotein Bridging Factor-1 (MBF-1) is a cofactor for nuclear receptors that regulate lipid metabolism. Mol. Endocrinol. 2002, 16, 1367-1377.
 132. L. Fajas, R.L. Landsberg, Y. Huss-Garcia, C. Sardet, J.A. Lees, J. Auwerx. E2Fs regulate adipocyte differentiation. Developmental Cell 2002, 3, 39-49
 133. A. Taberero, K. Schoonjans, L. Jesel, I. Carpusca, J. Auwerx, R. Andriantsitohaina. Activation of the peroxisome proliferator-activated receptor alpha protects against myocardial ischemic injury and improves endothelial vasodilatation. BMC Pharmacology 2002, 2, 10
 134. K. Ylitalo, I. Nuoto, J. Viikari, J. Auwerx, H. Vidal, M.R. Taskinen, C3, hormone-sensitive lipase, and peroxisome proliferator-activated receptor γ expression in adipose tissue of familial combined hyperlipidemia patients. Metabolism, 2002, 51, 664-670.
 135. C. Brendel, K. Schoonjans, E. Treuter, J. Auwerx. The small heterodimer partner (SHP) interacts with liver X receptor α and represses its transcriptional activity. Mol. Endocrinol. 2002, 16, 2065-2076.
 136. S. Eligini, M. Brambilla, C. Banfi, M. Camera, L. Sironi, S.S. Barbieri, J. Auwerx, E. Tremoli, S. Colli. Oxidized phospholipids inhibit cyclooxygenase-2 in human macrophages via nuclear factor- κ B/I κ B- and ERK2-dependent mechanisms. Cardiovasc. Res. 2002, 55, 406-415.
 137. T. Tanaka, T. Takeno, Y. Watanabe, Y. Uchiyama, T. Murakami, H. Yamashita, A. Suzuki, R. Aoi, H. Iwanari, S.Y. Jiang, M. Naito, K. Tachibana, T. Doi, A.I. Shulman, D.J. Mangelsdorf, R. Reiter, J. Auwerx, T. Hamakubo, T. Kodama. The Generation of Monoclonal Antibodies against Human Peroxisome Proliferator-activated Receptors (PPARs). J Atheroscler Thromb 2002; 9, 233-42
 138. F. Picard, M. Watanabe, K. Schoonjans, J. Lydon, B.W. O'Malley, J. Auwerx. Progesterone receptor knock-out mice have an improved glucose homeostasis secondary to β -cell proliferation. Proc. Natl. Acad. Sci. USA 2002, 15644-15648.
 139. L. Fajas, V. Egler, R. Reiter, J. Hansen, K. Kristiansen, M.-B. Debril, S. Miard, J. Auwerx. The retinoblastoma-histone deacetylase 3 complex inhibits the peroxisome proliferator-activated receptor gamma and adipocyte differentiation. Developmental Cell, 2002, 3,903-910.
 140. F. Picard, M. Géhin, J.-S. Annicotte, S. Rocchi, M.-F. Champy, B.W. O'Malley, P. Chambon, and J. Auwerx. SRC-1 and TIF2 control energy balance between white and brown adipose tissues. Cell 2002, 111, 931-941.
 141. K. Schoonjans, J.-S. Annicotte, T. Huby, O.A. Botrugno, E. Fayard, Y. Ueda, J. Chapman, J. Auwerx. Liver receptor homolog I controls the expression of the scavenger receptor class B type I. EMBO rep. 2002, 3, 1181-87.
 142. M. Schmuth, K. Schoonjans, Q.C. Yu, J.W. Fluhr, D. Crumrine, J.P. Hachem, J. Auwerx, P.M. Elias, K.R. Feingold. Role of peroxisome proliferator activated receptor alpha in epidermal development in utero. J. Invest. Dermatol. 2002, 119, 1298-1303.
 143. A. Meirhaeghe, L. Fajas, L. Gouilleux, D. Cottel, N. Helbecque, J. Auwerx, P. Amouyel. A functional polymorphism in a STAT5B site on the human PPAR γ 3 gene promoter affects height and lipid metabolism in a French population. Arterioscler. Thromb. Vasc. Biol. 2003, 23, 289-294.
 144. L. Fajas, V. Egler, R. Reiter, S. Miard, A.-M. Lefebvre, J. Auwerx. PPAR γ controls cell proliferation and apoptosis in an RB-dependent manner. Oncogene, 2003, 22, 4186-4193.
 145. L. Dubuquoy, E. A. Jansson, S. Deeb, S. Rakatobe, M. Karoui, J.-F. Colombel, J. Auwerx, S. Pettersson, P. Desreumaux. Impaired expression of the peroxisome proliferator-activated receptor γ in ulcerative colitis. Gastroenterology 2003, 124, 1265-1276.
 146. C. Banfi, J. Auwerx, F. Poma, E. Tremoli, L. Mussoni. Induction of plasminogen activator inhibitor 1 by the PPAR α ligand, Wy-14,643 is dependent on ERK1/2 signaling pathway. Thrombosis and Hemostasis, 2003, 90, 611-619.
 147. L Fajas, S. Miard, M. Briggs, J. Auwerx. Selective cyclo-oxygenase-2 inhibitors impair adipocyte differentiation through inhibition of the clonal expansion phase. J. Lipid Res. 2003 44, 1652-1659.
 148. G Woerly, K. Honda, M. Loyens, J-P. Papin, J. Auwerx, B. Staels, M. Capron, D. Dombrowicz.

- Peroxisome proliferator-activated receptors α and γ down-regulate allergic inflammation and eosinophil activation. *J. Exp. Med.* 2003, 198, 411-421
149. J.-S. Annicotte, E. Fayard, G.H. Swift, L. Selander, H. Edlund, T. Tanaka, T. Kodama, K. Schoonjans, J. Auwerx. The pancreatic-duodenal homeobox-1 (PDX-1) regulates the expression of the liver receptor homolog 1 (LRH-1) during pancreas development. *Mol. Cell. Biol.* 2003, 23, 6713-6724.
 150. E. Fayard, K. Schoonjans, J.-S. Annicotte, J. Auwerx. The liver receptor homolog 1 controls the expression of carboxyl ester lipase. *J. Biol. Chem.* 2003, 278, 35725-35731.
 151. H. Koutnikova, T.A. Cock, M. Watanabe, S. M. Houten, M.F. Champy, A. Dierich, J. Auwerx. Compensation by the muscle limits the metabolic consequences of lipodystrophy in PPAR γ hypomorphic mice. *Proc. Natl. Acad. Sci. USA* 2003, 100, 14457-14462.
 152. T. Tanaka, J. Yamamoto, S. Iwasaki, H. Asaba, H. Hamura, Y. Ikeda, M. Watanabe, K. Magoori, R. X. Ioka, K. Tachibana, Y. Watanabe, Y. Uchiyama, K. Sumi, H. Iguchi, S. Ito, T. Doi, T. Hamakubo, M. Naito, J. Auwerx, M. Yanagisawa, T. Kodama, J. Sakai. Activation of Peroxisome Proliferator-Activated Receptor δ induces fatty acid β -oxidation in skeletal muscle and attenuates diet-induced obesity and insulin resistance. *Proc. Natl. Acad. Sci. USA* 2003, 100, 15924-15929.
 153. M.B. Debril, L. Gelman, E. Fayard, J.S. Annicotte, S. Rocchi, J. Auwerx. Transcription factors and nuclear receptors interact with the SWI/SNF complex through the BAF60c subunit. *J. Biol. Chem.* 2004, 279, 16677-16686.
 154. B. Mascrez, N. Ghyselinck, M. Watanabe, J.S. Annicotte, P. Chambon, J. Auwerx, M. Mark. Ligand-dependent contribution of RXR β to cholesterol homeostasis in Sertoli cells. *EMBO reports* 2004, 5, 285-290.
 155. J.-S. Annicotte, K. Schoonjans, J. Auwerx. Expression of the liver X receptor alpha and beta in embryonic and adult mice. *Anat. Rec.* 2004, 277A, 312-316.
 156. K.T. Dalen, K. Schoonjans, S.M. Ulven, S. Weedon, T.G. Bentzen, H. Koutnikova, J. Auwerx, H.I. Nebb. Adipose tissue expression of the lipid droplet associating proteins S3-12 and perilipin is controlled by PPAR γ . *Diabetes* 2004, 53, 1243-1252.
 157. L. Fajas, J.-S. Annicotte, S. Miard¹, D. Sarru, M. Watanabe, J. Auwerx. Impaired pancreatic growth, β -cell mass and function in E2F1 $-/-$ mice. *J. Clin. Invest.*, 2004, 113, 1288-1295.
 158. M. Watanabe, S.M. Houten, L. Wang, A. Moschetta, D.J. Mangelsdorf, R.A. Heyman, D.D. Moore, J. Auwerx. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. *J. Clin. Invest.*, 2004, 113, 1408-1418.
 159. M. Schmuth, C.M. Haqq, W.J. Cairns, J.C. Holder, S. Dorsam, S. Chang, P. Lau, A.J. Fowler, G. Chuang, A.H. Moser, B.E. Brown, M. Mao-Qiang, Y. Uchida, K. Schoonjans, J. Auwerx, P. Chambon, T.M. Willson, P.M. Elias, K.R. Feingold. Peroxisome proliferator-activated receptor (PPAR)-beta/delta stimulates differentiation and lipid accumulation in keratinocytes. *J. Invest. Dermatol.* 2004, 122, 971-983.
 160. M.-F. Champy, M. Selloum, L. Piard, V. Zeitler, C. Caradec, P. Chambon, J. Auwerx. Mouse functional genomics requires standardization of mouse handling and housing conditions. *Mammalian Genome* 2004, 15, 768-783.
 161. S.H. Um, F. Frigerio, M. Watanabe, F. Picard, M. Joaquin, M. Stricker, S. Fumagalli, P.R. Allegrini, S. C. Kozma, J. Auwerx, G. Thomas. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. *Nature* 2004, 431, 200-205.
 162. O.A. Botrugno, E. Fayard, J.-S. Annicotte, C. Haby, T. Brennan, O. Wendling, T. Tanaka, T. Kodama, W. Thomas, J. Auwerx, K. Schoonjans. Synergy between LRH-1 and β -catenin induces cyclin-mediated cell proliferation. *Mol. Cell*, 2004, 15, 499-509.
 163. T.A. Cock, J. Back, F. Elefteriou, G. Karsenty, P. Kastner, S. Chan, J. Auwerx. Enhanced bone formation in lipodystrophic PPAR γ ^{hyp/hyp} mice relocates hematopoiesis to the spleen. *EMBO reports*, 2004, 10, 1007-1012.
 164. J. Auwerx, P. Avner, R. Baldock, A. Ballabio, R. Balling, M. Barbacid, A. Berns, A. Bradley, S. Brown, P. Carmeliet, P. Chambon, R. Cox, D. Davidson, K. Davies, D. Duboule, J. Forejt, F. Granucci, N. Hastie, M.H. De Angelis, I. Jackson, D. Kioussis, G. Kollias, M. Lathrop, U. Lendahl, M. Malumbres, H. Von Melchner, W. Muller, J. Partanen, P. Ricciardi-Castagnoli, P. Rigby, B. Rosen, N. Rosenthal, B. Skarnes, A.F. Stewart, J. Thornton, G. Tocchini-Valentini, E. Wagner, W. Wahli, W. Wurst. The European dimension for the mouse genome mutagenesis program. *Nat. Genet.* 2004, 36, 925-927

165. A. Jellali, H. Meziane, A. Ouagazzal, S. Rousseau, R. Romand, J. Auwerx, J. Sahel, P. Chambon. The optomotor response: A robust first-line visual screening method for mice. *Vision Res.* 2005, 45, 1439-1446.
166. K. Schoonjans, L. Dubuquoy, J. Mebis, E. Fayard, O. Wendling, C. Haby, K. Geboes, J. Auwerx. Liver Receptor Homolog 1 contributes to colon tumor formation. *Proc. Natl. Acad. Sci USA* 2005, 102, 2058-2062.
167. S. Dharancy, M. Malapel, G. Perlemuter, T. Roskams, Y. Cheng, L. Dubuquoy, P. Podgevin, F. Conti, V. Canva, L. Gambiez, P. Mathurin, J.C. Paris, K. Schoonjans, Y. Calmus, S. Pol, J. Auwerx, P. Desreumaux. Impaired expression of the peroxisome proliferators-activated receptor alpha during hepatitis virus infection. *Gastroenterology* 2005, 128, 334-42.
168. C. Rousseaux, B. Lefebvre, L. Dubuquoy, P. Lefebvre, O. Romano, J. Auwerx, P. Chambon, W. Wahli, G.C. Naccari, P. Chavatte, A. Farce, P. Bulois, A. Cortot, J.F. Colombel, P. Desreumaux. Intestinal anti-inflammatory effect of 5-aminosalicylic acid is dependent on PPAR γ expression and activation. *J. Exp. Med.* 2005, 201, 1205-15.
169. M.W.T. Tanck, L. Fajas, C. Janot, N. Helbecque, D. Cotel, J. Auwerx, P. Amouyel, J. Dallongeville. Study of a new PPAR γ 2 promoter polymorphism and haplotype analysis in a French population. *Mol. Gen. Metab.* 2005, 85, 140-148.
170. C. Delaye-Orthez, J. Becker, I. Guenon, V. Lagente, J. Auwerx, N. Frossard, F. Pons. PPAR α downregulates airway inflammation induced by lipopolysaccharide in the mouse. *Resp. Res.*, 2005, 6, 91.
171. M-B. Debril, L. Dubuquoy, J.N. Feige, W. Wahli, B. Desvergne, J. Auwerx and L. Gelman. Scaffold attachment factor B1 directly interacts with nuclear receptors in living cells and represses transcriptional activity. *J Mol Endocrinol*, 2005, 35, 501-515
172. M. Watanabe, S.M. Houten, C. Matak, M.A. Christoffolete, B.W. Kim, H. Sato, N. Messaddeq, J.W. Harney, O. Ezaki, T. Kodama, K. Schoonjans, A.C. Bianco, J. Auwerx. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. *Nature*, 2005, 439, 484-489.
173. A. Rodriguez, A. Duran, M. Selloum, M.-F. Champy, F.J. Diez-Guerra, J.M. Flores, M. Serrano, J. Auwerx, M.T. Diaz-Meco, J. Moscat. Mature-onset obesity and insulin resistance in mice deficient in the signaling adapter p62. *Cell Metabolism*, 2006, 3, 211-22.
174. C. Loichot, L. Jesel, A. Tesse, A. Tabernero, K. Schoonjans, G. Roul, I Carpusca, J. Auwerx, R. Andraiantsitohaina. Deletion of peroxisome proliferators-activated receptor alpha induces an alteration of cardiac functions. *Am. J. Physiol. Heart Circ. Physiol.* 2006, 291, H161-6.
175. A. Coste, M.C. Antal, S. Chan, P. Kastner, M. Mark, B. O'Malley, J. Auwerx. Absence of the steroid receptor coactivator 3 (SRC-3) induces B cell lymphoma. *EMBO J.*, 2006, 25, 2453-64.
176. J.F. Louet, A. Coste, L. Amazit, M. Tannour-Louet, R.C. Wu, S.Y. Tsai, M.J. Tsai, J. Auwerx, B. O'Malley. Oncogenic steroid receptor coactivator-3 is a key regulator of the white adipogenic program. *Proc. Natl. Acad. Sci. USA*. 2006, 103, 17868-17873
177. P. Peltola, J. Pihlajamaki, H. Koutnikova, E. Ruotsalainen, U. Salmenniemi, I. Vauhkonen, S. Kainulainen, H. Gylling, T.A. Miettinen, J. Auwerx, and M. Laakso. Visceral obesity is associated with high levels of serum squalene. *Obesity*, 2006, 14, 1155-63.
178. M. Lagouge, C. Argmann, Z. Gerhart-Hines, H. Meziane, C. Lerin, F. Daussin, N. Messadeq, J. Milne, P. Lambert, P. Elliot, B. Geny, M. Laakso, P. Puigserver, J. Auwerx. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1 α . *Cell*, 2006, 127, 1109-1122.
179. N. Grarup, M. K. Andersen, C. H. Andreasen, A. Albrechtsen, K. Borch-Johnsen, T. Jørgensen, J. Auwerx, O. Schmitz, T. Hansen, O. Pedersen. Studies of the relationship between the common *DIO2* Thr92Ala polymorphism and type 2 diabetes, obesity and insulin resistance in 7,342 Danish white subjects: indication of gene-gene interaction with the *ADRB2* Gly16Arg variant on levels of fasting glycaemia in the general population. *J. Clin Endocrinol. Metab.*, 2007, 92, 363-366.
180. D. H. Volle, R. Duggavathi, B.C. Magnier, S.M. Houten, C. L. Cummins, J.-M. Lobaccaro, G. Verhoeven, K. Schoonjans, J. Auwerx. The small heterodimer partner is a gonadal gatekeeper of sexual maturity in male mice. *Genes & Dev.*, 2007, 21, 303-315.
181. S. Dubrac, P. Stoitzner, D. Pirkebner, A. Elentner, K. Schoonjans, J. Auwerx, S. Saeland, P. Hengster, P. Fritsch, N. Romani, M. Schmutz. Peroxisome proliferator-activated receptor alpha

- activation inhibits Langerhans cell function. J Immunol. 2007, 178, 4362-4372.
182. S. M. Houten, D.H. Volle, C.L. Cummins, D.J. Mangelsdorf, J. Auwerx. In vivo imaging of FXR activity reveals the ileum as the primary bile acid signaling tissue. Mol. Endocrinol. 2007, 21, 1312-1323.
 183. A. Berry, P. Balard, A. Coste A, D. OLAGNIE, C. Lagane, H. Authier, F. Benoit-Vical, J.C. Lepert, J.P. Seguela, J.F. Magnaval, P. Chambon, D. Metzger, B. Desvergne, W. Wahli, J. Auwerx, B. Pipy. IL-13 induces expression of CD36 in human monocytes through PPAR γ activation. Eur. J. Immunol., 2007, 37, 1642-1652.
 184. P. Boucher, W.P. Li, R. L. Matz, Y. Takayama, J. Auwerx, R.G.W. Anderson, J. Herz. LRP1 functions as an atheroprotective integrator of TGF β and PDGF signals in the vascular wall: implications for Marfan syndrome. PLoS ONE 2(5) e448 doi:10.1371/journal.pone.0000448
 185. N. Dali-Youcef, C. Matak, A. Coste, N. Messadeq, S. Giroud, S. Blanc, C. Koehl, P. Chambon, L. Fajas, D. Metzger, K. Schoonjans, J. Auwerx. Adipose tissue specific inactivation of the retinoblastoma protein protects against diabetes due to increased energy expenditure. Proc. Natl. Acad. Sci. USA, 2007, 104, 10703-10708.
 186. A. Coste, L. Dubuquoy, R. Barnouin, J.S. Annicotte, B. Magnier, M. Notti, N. Corazza, M.C. Antal, D. Metzger, P. Desreumaux, T. Brunner, J. Auwerx, K. Schoonjans. LRH-1 mediated glucocorticoid synthesis in enterocytes protects against inflammatory bowel disease. Proc. Natl. Acad. Sci. USA, 2007, 104, 13098-13103.
 187. R. Pellicciari, H. Sato, A. Gioiello, G. Costantino, A. Macchiarulo, B.M. Sadeghpour, G. Giorgi, K. Schoonjans, and J. Auwerx. J. Med. Chem., 2007, 50, 4265-4268.
 188. H. Sato, C. Genet, A. Strehle, C. Thomas, A. Lobstein, A. Wagner, C. Mioskowski, J. Auwerx, R. Saladin. Anti-hyperglycemic activity of a TGR5 agonist isolated from *Olea Europea*. Biochem. Biophys. Res. Commun. 2007, 362, 793-798.
 189. C. Matak, B. Magnier, S.M. Houten, J.-S. Annicotte, C. Argmann, C. Thomas, H. Overmars, W. Kulik, D. Metzger, J. Auwerx, K. Schoonjans. Compromised intestinal lipid absorption in mice with a liver-specific deficiency of the Liver Receptor Homolog 1. Mol. Cell Biol. 2007, 27, 8330-8339.
 190. P. Bai, S.M. Houten, A. Huber, V. Schreiber, M. Watanabe, B. Kiss, G. de Murcia, J. Menissier-de Murcia. PARP-2 controls adipocyte differentiation and adipose tissue function through the regulation of the activity of the RXR/PPAR γ heterodimer. J. Biol. Chem. 2007, 282, 37738-37746.
 191. F. Gofflot, N. Chartoire, L. Vasseur, S. Heikkinen, D. Dembele, J. Le Merre, J. Auwerx. Systematic gene expression mapping clusters nuclear receptors on the basis of their function in the brain. Cell, 2007, 131, 405-418.
 192. C. Delayre-Orthez, J. Becker, J. Auwerx, N. Frossard, F. Pons. Suppression of allergen-induced airway inflammation and immune response by the peroxisome proliferators-activated receptor alpha agonist fenofibrate. Eur. J. Pharmacol. 2007, 581, 177-184.
 193. H. Sato, A. Macchiarulo, C. Thomas, A. Gioiello, M. Une, A. F. Hofmann, R. Saladin, K. Schoonjans, R. Pellicciari, J. Auwerx. Novel potent and selective bile acid derivatives as TGR5 agonists : biological screening, structure-activity relationship and molecular modeling studies. J. Med. Chem., 2008, 51, 1831-41.
 194. A. Coste, C. Lagane, C. Filipe, H. Authier, A. Gales, J. Bernad, V. Douin-Echinard, J.C. Lepert, P. Balard, M.D. Linas, J.F. Arnal, J. Auwerx, B. Pipy. IL-13 attenuates gastrointestinal candidiasis in normal and immunodeficient RAG2^{-/-} mice via peroxisome proliferator-activated gamma activation. J. Immunol., 2008, 180, 4939-47.
 195. M.F. Champy, M. Selloum, V. Zeitler, C. Caradec, B. Jung, S. Rousseau, L. Pouilly, T. Sorg, J. Auwerx. Genetic background determines metabolic phenotypes in the mouse. Mamm. Genome, 2008, 19, 318-331.
 196. S. Mandillo, V. Tucci, S.M. Holter, H. Meziane, M. Al Banachaabouchi, M. Kallnik, H.V. Lad, P.M. Nolan, A.M. Ouagazzal, E.L. Coghill, K. Gale, E. Golini, S. Jacquot, W. Krezel, A. Parker, F. Riet, I. Schneider, D. Marazziti, J. Auwerx, S.D. Brown, P. Chambon, N. Rosenthal, G. Tocchini-Valentini, W. Wurst. Reliability, Robustness and Reproducibility in mouse behavioral phenotyping: a cross-laboratory study. Physiol Genomics. 2008, 34, 243-255.
 197. A. Macchiarulo, A. Gioiello, C. Thomas, A. Massarotti, R. Nuti, E. Rosatelli, P. Sabbatini, K. Schoonjans, J. Auwerx, R. Pellicciari. Molecular field analysis and 3D-quantitative structure-activity

- relationship study (MFA 3D-QSAR) unveil novel features of bile acid recognition at TGR5. J. Chem. Inf. Model., 2008, 48, 1792-1801.
198. R. Duggavathi, D.H. Volle, C. Matak, M.C. Antal, N. Messadeq, J. Auwerx, B.D. Murphy, K. Schoonjans. Liver receptor homolog 1 is essential for ovulation. Genes Dev., 2008, 22, 1871-6.
199. A. Coste, J.F. Louet, M. Lagouge, C. Lerin, M.C. Antal, H. Meziane, K. Schoonjans, P. Puigserver, B. W. O'Malley, J. Auwerx. The genetic ablation of SRC-3 protects against obesity and improves insulin sensitivity by reducing the acetylation of PGC-1 α . Proc. Natl. Acad. Sci. USA, 2008, 105, 17187-17192.
200. J.N. Feige, M. Lagouge, C. Canto, A. Strehle, S. Houten, J. Millne, P.D. Lambert, C. Matak, P.J. Elliot, J. Auwerx. Specific SIRT activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metabolism, 2008, 8, 347-358.
201. P. Polak, N. Cybulski, J.N. Feige, J. Auwerx, M.A. Ruegg, M.N. Hall. Adipose-specific knockout of raptor results in lean mice with enhanced mitochondrial respiration. Cell Metabolism, 2008, 8, 399-410
202. J. Terrand, V. Bruban, L. Zhou, W. Gong, Z. El Asmar, P. May, K. Zurhove, P. Hafner, C. Philippe, E. Woldt, R.L. Matz, C. Gracia, D. Metzger, J. Auwerx, J. Herz, P. Boucher. LRP1 controls intracellular cholesterol storage and fatty acid synthesis through modulation of Wnt signaling. J. Biol. Chem., 2009, 284, 381-388.
203. S. Heikkinen, C. Argmann, J.N. Feige, H. Koutnikova, M.F. Champy, N. Dali-Youcef, E.S. Schadt, M. Laakso, J. Auwerx. The Pro12Ala PPAR γ 2 variant determines metabolism at the gene-environment interface. Cell Metabolism, 2009, 9, 88-98.
204. C. Canto, Z. Gerhart-Hines, J.N. Feige, M. Lagouge, L. Noriega, J.C. Millne, P. Puigserver, J. Auwerx. AMPK regulates energy expenditure by modulating NAD⁺ metabolism and SIRT1 activity. Nature, 2009, in the press.

Reviews, Chapters, and Editorials

1. J. Auwerx, H. Ector en M. Demedts. Cardiale sarcoidosis. Tijdschrift voor Geneeskunde.1984, 40, 1035-1039.
2. J. Auwerx, R. Bouillon. Mineral and bone metabolism in thyroid disease: a review. Quart. J. Med. , 1986, 60, 737-752.
3. J. Auwerx, L. Lauweryns, M. Demedts. Familial interstitial lung disease. Bull. Fijnvl. Longafw., 1986, 7, 36-38.
4. J. Auwerx, J. Brunzell, R. Bouillon, M. Demedts. Familial hypocalciuric hypercalcemia or benign hypercalcemia; a review. Post Grad. Med. J., 1987, 63, 835-840.
5. H. De Loof, J. Auwerx, M. Rosseneu, G. Verhoeven. Molecular genetics of lipid disorders: new perspectives in atherosclerosis. Molecular Genetics (Life Sci. Adv.), 1987, 6, 113-127.
6. J. Auwerx. The THP-1, monocytic leukemia cell line, a multifaceted model to study macrophage differentiation. Experientiae 1991, 47, 22-31.
7. J. Auwerx, K. Schoonjans. Apolipoprotein B and LDL, an atherogenic connection. Acta Clin. Belgica 1991, 46, 355-358.
8. J. Auwerx, P. Leroy, K. Schoonjans. Lipoprotein lipase, a bright future with molecular biology. Crit. Rev. Clin. Labor. Sci. 1992, 29, 243-268.
9. J. Auwerx. Regulation of gene expression by fatty acids and fibric acid derivatives: an integrative role for PPAR. Hormone Research 1992, 38, 269-277.
10. J. Auwerx, K. Schoonjans, L. Troonbeeckx. Heeft apolipoproteine E genotypering een klinisch belang ? Tijdschrift voor Geneeskunde 1993, 49, 275-277.
11. B. Staels, R. Saladin, J. Auwerx. Contrôle hormonal des gènes impliqués dans le métabolisme lipoprotéique chez le rat. Cahiers de Nutrition et Diététique , 1995, 30, 43-47.

12. J. Auwerx, G. Martin, M. Guerre-Millo, B. Staels. Transcription, adipocyte differentiation, and obesity. J. Mol. Med. 1996, 74,347-352.
13. K. Schoonjans, B. Staels, J. Auwerx. Role of the peroxisome proliferator activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J. Lipid Res. 1996,37, 907-925.
14. M. Guerre-Millo, R. Saladin, B. Staels, J. Auwerx. Les facteurs régulateurs du gène ob. Médecine/Sciences 1996. 12, 383-385
15. T. Lemberger, O. Braissant, C. Juge-Aubry, H. Keller, R. Saladin, B. Staels, J. Auwerx, A.G. Burger, C.A. Meier, W. Wahli. PPAR tissue distribution and interactions with other hormone-signalling pathways. Ann. NY Acad. Sci. 1996, 804, 231-251
16. K. Schoonjans, B. Staels, J. Auwerx. The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim. Biophys. Acta 1996, 1302,93-109.
17. B. Staels, A. Van Tol, J. C. Fruchart, J. Auwerx. Effects of hypolipidemic drugs on the expression of genes involved in high density lipoprotein metabolism in rat. Isr J. Med. Sci. 1996, 32, 490-498.
18. G. Martin, B. Staels, M. Guerre-Millo, J. Auwerx. Transcription, différenciation adipocytaire et obésité. Médecine/ Sciences 1996. 12, 885-890.
19. R. Saladin, B. Staels, J. Auwerx, M. Briggs. Regulation of ob gene expression in rodents and human. Horm. Metab. Res. 1996, 28, 638-641.
20. J. Auwerx, K. Schoonjans, J. C. Fruchart, B. Staels. Regulation of triglyceride metabolism by PPARs: fibrates and thiazolidinediones have distinct effects. J. Ath. & Thromb. 1996, 3, 81-89.
21. M. Guerre-Millo, B. Staels, J. Auwerx. New insights into obesity genes. Diabetologia, 1996, 39, 1528-1531.
22. G. Martin, I. Shviro, B. Staels, J. Auwerx. Hyperlipidémie combinée familiale. Annales d'Endocrinologie, 1997, 58, 283-286.
23. B. Staels, K. Schoonjans, J.C. Fruchart, J. Auwerx. The effects of fibrates and thiazolidine diones on plasma triglyceride metabolism are mediated by distinct peroxisome proliferator activated receptors. Biochimie, 1997, 79, 95-99.
24. A. Lefebvre, R. Saladin, M. Briggs, B. Staels, J. Auwerx. Régulation de l'expression du gène ob. Diététique et Médecine, 1997, 11-15.
25. L. Gelman, B. Staels, J. Auwerx. Role des cofacteurs transcriptionnels dans la transduction des signaux hormonaux par les récepteur nucléaires. Médecine/ Sciences , 1997, 13, 961-970.
26. B. Staels, J. Auwerx. Role of fibrates in the pharmacological regulation of lipoprotein metabolism by fibrates and thiazolidinediones. Curr. Pharmac. Design 1997, 3, 1-4.
27. K. Schoonjans, G. Martin, B. Staels, J. Auwerx. Peroxisome proliferator activated receptors, orphans with ligands and functions. Curr. Opin. Lipid. 1997, 8, 159-166.
28. J. Auwerx, B. Staels. Leptin. Lancet, 1998,351, 737-742.
29. L. Fajas, J. C. Fruchart, J. Auwerx. Transcriptional control of adipogenesis. Curr. Opin. Cell Biol. 1998, 10, 165-173.
30. G. Martin, K. Schoonjans, B. Staels, J. Auwerx. PPAR γ activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes. Atherosclerosis, 1998, 137, S75-S80.
31. J. Dallongeville, J.C. Fruchart, J. Auwerx. Leptin a pleiotropic hormone: physiology, pharmacology, and strategy for discovery for leptin modulators. J. Med. Chem, 1998, 41, 5337-5352.
32. B. Staels, J. Dallongeville, J. Auwerx, K. Schoonjans, E. Leitersdorf, Fruchart, J.C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation, 1998, 98, 2088-2093
33. C. R Sirtori, M. R. Lovati, C. Manzoni, E. Gianazza, A. Bondioli, B. Staels, J. Auwerx. Reduction of serum cholesterol by soy proteins: clinical experience and potential mechanisms. Nutr. Metab. Cardiovasc. Dis. 1998, 8, 334-340.
34. C. Brendel, J.C. Fruchart, J. Auwerx, K. Schoonjans. Régulation transcriptionnelle du métabolisme du cholestérol. Médecine/Sciences, 1999,15, 5661 .
35. J. Auwerx. PPAR γ the ultimate thrifty gene. Diabetologia 1999, 42, 1033-1049
36. L. Gelman, J.-C. Fruchart, J. Auwerx. An update about the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancers. Current Molecular Life Sciences, 1999, 55, 932-943

37. L. Madsen, L. Froyland, H. Kryvi, J. Auwerx, B. Staels, R.K. Berge The mitochondrion is the principle target for nutritional and pharmacological control of plasma triglyceride. Lipids, 1999, 34, S167
38. L. Gelman, J. Auwerx. Peroxisome proliferator-activated receptors: mediators of a fast food impact on gene regulation. Curr. Opin. Clin. Nutr. Metab. Care 1999, 2, 307-312.
39. S. Rocchi, J. Auwerx. Peroxisome proliferator-activated receptor gamma: aversatile metabolic regulator. Ann. Med. 1999, 342-351.
40. K. Schoonjans, J. Auwerx. Thiazolidinediones, an update. The Lancet 2000, 355, 1008-10.
41. S. Rocchi, J. Auwerx. Peroxisome proliferator-activated receptor gamma, the ultimate liason between fat and transcription. Br. J. Nutr. 2000, 84 S223-S227.
42. E. Fayard, K. Schoonjans, J. Auwerx. Xol INXS: role of liver X and farnesaol X receptors. Curr. Opin. Lipidol. 2001, 2, 113-120.
43. M.B. Debril, J.P. Renaud, L. Fajas, J. Auwerx. The pleiotropic functions of peroxisome proliferator-activated receptor gamma. J. Mol. Med. 2001, 79, 30-47.
44. L. Fajas, M.B. Debril, J. Auwerx. Peroxisome proliferator-activated receptor gamma: from adipogenesis to carcinogenesis. J. Mol. Endocrinol. 2001, 27, 1-9.
45. L. Fajas, M.B. Debril, J. Auwerx. PPARgamma: an essential role in metabolic control. Nutr. Metab. Cardiovasc. Dis. 2001, 11, 64-69.
46. H. Koutnikova & J. Auwerx. Regulation of adipocyte differentiation. Ann. Med. 2001, 33, 556-561.
47. C. Brendel, L. Gelman, J. Auwerx, S. Rocchi. Rôle des PPARs dans l'inflammation et le cancer. Médecine et Thérapeutique, endocrinology, 2001, 19-25.
48. J. Auwerx. PPAR γ in the gastrointestinal tract: gain or pain ? Am. J. Physiol. (Gastrointest. Liver Physiol). 2002, 282, G581-G585.
49. F. Picard, J. Auwerx. PPAR γ and glucose homeostasis. Annu. Rev. Nutrition 2002, 22, 167-197.
50. K. Schoonjans and J. Auwerx. A sharper image of SHP. Nature Med. 2002, 8, 789-791.
51. G. Francis, J-S. Annicotte, J. Auwerx. Liver X receptors: Xcreting Xol to combat atherosclerosis. Trends Mol. Medicine 2002, 8, 455-458.
52. L. Dubuquoy, S. Dharancy, S. Nutten, S. Pettersson, J. Auwerx, P. Desreumaux. Role of the peroxisome proliferator-activated receptor gamma and retinoid X receptor heterodimer in hepatogastroenterological diseases. The Lancet, 2002, 360, 1410-1418.
53. T. Fournier, L. Pavan, A. Tarrade, K. Schoonjans, J. Auwerx, C. Rochette-Egly, D. Evain-Brion. The role of PPARgamma/RXRalpha heterodimers in the regulation of trophoblast invasion. Ann. NY Acad. Sci 2002, 973, 26-30.
54. G. Francis, E. Fayard, F. Picard, J. Auwerx. Nuclear receptors and the control of metabolism. Annu. Rev. Physiol. 2003, 65, 261-311.
55. G. Francis, J-S. Annicotte, J. Auwerx.. PPAR agonists in the treatment of atherosclerosis. Curr. Opin. Pharmacology. 2003, 3, 186-91
56. G. Francis, J-S. Annicotte, J. Auwerx. PPAR α effects on the heart and other vascular tissues. Am. J. Physiol. 2003, 285, H1-9.
57. T.-A. Cock and J. Auwerx. Leptin: cutting the fat of the bone. The Lancet, 2003, 362, 1572-1574.
58. J. Auwerx, J. Drouin, V. Laudet. Récepteurs à la Provençale. EMBO reports 2003, 4, 1122-1126.
59. T.-A. Cock, S. Houten, J. Auwerx. Peroxisome proliferators-activated receptor γ : too much of a good thing harms. EMBO reports 2004, 5, 142-147.
60. S. Houten, J Auwerx. PGC-1 α : turbocharging mitochondria. Cell 2004, 119, 5-7.
61. S. Farmer, J. Auwerx. Adipose tissue: new therapeutic targets from molecular and genetic studies. Obes. Rev. 2004, 4; 189-196.
62. S. Houten, J. Auwerx. The enterohepatic nuclear receptors are major regulators of the enterohepatic circulation of bile salts. Ann. Med. 2004, 36, 482-491.
63. E. Fayard, J. Auwerx, K. Schoonjans. LRH-1 : an orphan nuclear receptor involved in development, metabolism, and steroidogenesis. Trends in Cell Biology, 2004, 14, 250-260.
64. S. Morozova, I. Suc-Royer, J. Auwerx. Les modulateurs du métabolisme du cholesterol dans le traitement de l'athérosclérose. Médecine et Sciences, 2004, 20: 685-690
65. C. Knouff, J Auwerx. Peroxisome proliferators-activated receptor gamma calls for activation in moderation: lessons from Genetics and pharmacology. Endocrine Reviews, 2004, 25, 899-918.
66. C.A. Argmann, T.A. Cock, J. Auwerx. Peroxisome proliferators-activated receptor gamma: the more

- the merrier ? Eur. J. Clin. Invest. 2005, 35, 82-92.
67. C.A. Argmann, P. Chambon, J. Auwerx. Mouse phenogenomics: the fast track to 'systems' metabolism. Cell Metabolism, 2005, 2, 349-360.
 68. J. Auwerx. Improving metabolism by increasing energy expenditure. Nature Medicine, 2006, 12, 44-45
 69. S. Houten, M. Watanabe, J. Auwerx.. Endocrine functions of bile acids. EMBO J., 2006, 25, 1419-25.
 70. C. Argmann, J. Auwerx. Insulin action: SIRT4 gets in on the act. Cell, 2006, 126, 837-839.
 71. L. Michalik, J. Auwerx, J.P. Berger, V. K. Chatterjee, C.K. Glass, F.J. Gonzalez, P.A. Grimaldi, T. Kadowaki, M.A. Lazar, S. O'Rahilly, C.N.A. Palmer, J. Plutzky, J.K. Reddy, B.M. Spiegelman, B. Staels, W. Wahli. International union of pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacological Reviews 2006, 58, 726-741.
 72. C. Argmann, A. Dierich, J. Auwerx. Uses of forward and reverse genetics in mice to study gene function. Curr. Protoc. Mol. Biol. 2006, Chapter 29, Unit 29A.1.
 73. C. Argmann, J. Auwerx. Minimizing variation due to genotype and environment. Curr. Protoc. Mol. Biol. 2006, Chapter 29, Unit 29A.2.
 74. C. Argmann, J. Auwerx. Collection of blood and plasma from the mouse. Curr. Protoc. Mol. Biol. 2006, Chapter 29, Unit 29A.3.
 75. C. Argmann, M.F. Champy, J. Auwerx. Evaluation of energy homeostasis. Curr. Protoc. Mol. Biol. 2006, Chapter 29, Unit 29B.1.
 76. C. Argmann, S.M. Houten, M.F. Champy, J. Auwerx. Lipid and bile acid analysis. Curr. Protoc. Mol. Biol. 2006, Chapter 29, Unit 29B.2.
 77. C. Antal, M. Teletin, O. Wendling, M. Dgheem, J. Auwerx, M. Mark. Tissue collection for systematic phenotyping in the mouse. Curr. Protoc. Mol. Biol. 2007, Chapter 29, Unit 29A.4.
 78. M. Mark, M. Teletin, C. Antal, O. Wendling, J. Auwerx, S. Heikkinen, K. Khetchioumian, C.A. Argmann, M. Dgheem. Histopathology in mouse metabolic investigations. Curr. Protoc. Mol. Biol. 2007, Chapter 29, Unit 29B.4.
 79. S. Heikkinen, C. Argmann, M.F. Champy, J. Auwerx. Evaluation of glucose homeostasis. Curr. Protoc. Mol. Biol. 2007, Chapter 29, Unit 29B.3.
 80. J. Feige and J. Auwerx. Transcriptional coregulators in the regulation of energy homeostasis. Trends in Cell Biology, 2007, 17, 292-301.
 81. S. Rasouri, M. Lagouge, J. Auwerx. SIRT1/PGC-1: un axe neuroprotecteur. Medecine & Sciences, 2007, 10, 840-844.
 82. N. Dali-Youcef, M. Lagouge, S. Froehlich, C. Koehl, K. Schoonjans, J. Auwerx. Sirtuins: the magnificent seven, function, metabolism and longevity. Ann Med., 2007, 39, 335-345.
 83. H. Yamamoto, K. Schoonjans, J. Auwerx. Sirtuin functions in health and disease. Mol. Endocrinol., 2007, 21, 1745-1755.
 84. S. Heikkinen, J. Auwerx, C.A. Argmann. PPAR γ in human and mouse physiology. Biochem. Biophys. Acta, 2007, 1771,999-1013.
 85. J. Feige, J. Auwerx. Dissirting on LXR and cholesterol metabolism. Cell Metabolism 2007, 6, 343-345.
 86. C. Canto, J. Auwerx. Glucose restriction: Longevity SIRTainly but without building muscle. Developmental Cell 2008, 14, 642-644.
 87. J. Feige, J. Auwerx. Transcriptional targets of sirtuins in the coordination of mammalian physiology. Curr. Opin. Cell Biol. 2008, 20, 303-309.
 88. C. Thomas, R. Pellicciari, M. Pruzanski, J. Auwerx, K. Schoonjans. Targeting bile-acid signalling for metabolic diseases. Nat Rev. Drug Discov. 2008, 678-93.
 89. C. Canto, J. Auwerx. PGC-1 α , SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr. Opin. Lipidol. 2009, 20, 98-105

Books, Monographs, and Text Books

1. M. Demedts, J. Auwerx en J.L. Ceuppens. Interstitiele longaandoeningen. In: Aanwinsten in de inwendige geneeskunde, nr. 9, Ed. Stafleu's Wetensch. Uitg., Alphen aan de Rijn, 1982, pp.79-121.
2. J. Brunzell, J. Auwerx, S. Babirak, S. Deeb, W. Fujimoto, M. Hayden. Familial lipoprotein lipase deficiency. In: Proceedings of the 8th International Symposium on Atherosclerosis, Springer Verlag, 1987, 265-267.
3. R. Bouillon, B. Nyomba, J. Verhaeghe, J. Auwerx. Calcium and vitamin D metabolism in diabetes mellitus. In: Calcitropic hormones and calcium metabolism, Ed. M. Cecchetti et al., Bi & Gi Med. Scient. Publ., Verona, 1988, 61-64.
4. J. Auwerx, L. Troonbeeckx. Heeft apolipoproteine E genotypering een klinisch belang. In: Aanwinsten in de inwendige geneeskunde, nr. 18, Postgraduaat Centrum voor Interne Geneeskunde KULeuven, 1991, 215-219.
5. P. Sassone-Corsi, S.J. Busch, F. Schlotter, J. Auwerx, B. Mellstrom, N.S. Foulkes, J.R. Naranjo. Nuclear oncogenes as transcription factors. In: Modulating factors in multistage carcinogenesis, Plenum press, 1994.
6. B. Staels and J. Auwerx. Hormonal control of genes involved in lipoprotein metabolism in the rat. In: Hormones in lipoprotein metabolism. Springer Verlag, 1993,9-15.
7. J. Auwerx, P. Sassone-Corsi. Factors modulating AP-1 activity. In: The fos and jun family of transcription factors. CRC press, 1994, 41-48.
8. J. Auwerx, K. Schoonjans, B. Staels. Regulation of liver lipoprotein lipase gene expression. In: Atherosclerosis X, Springer Verlag, 1995, 241-245
9. J.C. Fruchart, V. Clavey, G. Luc, J. Dallongeville, B. Staels, J. Auwerx. Apolipoprotein C-III, an important player in lipoprotein metabolism. In: Drugs affecting lipid metabolism, Ed. A.M. Gotto, R. Paoletti, L.C. Smith, A.L. Catapano, A.S. Jackson, Kluwer Academic Publishers, 1996, 631-638
10. B. Staels, J.C. Fruchart, J. Auwerx. Fatty acids as transcriptional regulators of the lipoprotein lipase and apo C-III genes: consequences for plasma triglyceride metabolism. In: Omega-3, lipoproteins and atherosclerosis, Ed. J. Davignon, J. C. Fruchart, J.M. Ordovas, John Libbey, Paris, 1996, 41-48.
11. J. Auwerx, B. Staels, R. Saladin, M. Briggs. Leptin In: Human Cytokines Volume III, Ed. B. Aggarwal, Blackwell Science , 1998, 189-206
12. J. Auwerx, J. Dallongeville, J.C. Fruchart, B. Staels. Mechanisms of the hypolipidemic action of fibrates. In: Multiple risk factors in cardiovascular disease. Ed A.M. Gotto, Kluwer, 1998, 9-15.
13. G. Martin, K. Schoonjans, B. Staels, J. Auwerx. PPAR activators improve glucose homeostasis by changing fatty acid partitioning. In: Atherosclerosis XI. Ed. B. Jacotot, D. Mathé, J.C. Fruchart, Elsevier, 1998, 35-47.
14. B. Staels, J. Auwerx, J.C. Fruchart. Molecular mechanisms of action of fenofibrate. In: Atherosclerosis XI. Ed. B. Jacotot, D. Mathé, J.C. Fruchart, Elsevier, 1998, 249-257.
15. S. Rocchi, J. Auwerx. Peroxisome proliferator-activated receptor γ , the ultimate liason between fat and transcription. In: Common disease: genetic and pathogenetic aspects of multifactorial diseases. Ed. H. Imura, M. Kasuga, K. Nakao, Elsevier, 1999, 169-179
16. J. Auwerx. Altered fatty acid partitioning by PPAR activators improves glucose homeostasis : a case for PPAR γ and α coagonists. In : Insulin resistance, metabolic diseases and diabetic complications. Ed. G. Crepaldi, A. Tiengo, S. Del Prato, Elsevier Science B.V., 1999, 167-172
17. L. Gelman, C. Brendel, J.C. Fruchart, J. Auwerx. Les dyslipidémies. In: Biologie Moléculaire en Biologie Clinique. III Applications ene Génétique. Ed. M. Bogard, J. Lamoril. Elsevier, 1999, 185-196.
18. C. Brendel, J. Auwerx. Insulinorésistance, le PPAR γ : un maître contrôleur. In: L'Impact de la nutrition sur la santé. Ed. K. Descheemaeker, C. Provoost. Garant, 2000, 119-124.
19. J. Auwerx, D. Mangelsdorf. X-ceptors, nuclear receptors for metabolism. In: Atherosclerosis XII. Ed. S. Stemme, A.G. Olson. Elsevier, 2000, 21-39.
20. H. Koutnikova, E. Fayard, J. Lehmann, J. Auwerx. Serial analysis of gene expression and gene trapping to identify nuclear receptor target genes. In: Methods in Enzymology, Vol 364: Nuclear Receptors. Ed. D. W. Russell , D. J. Mangelsdorf. Elsevier, 2003, pg 299-322.
21. T.-A. Cock, J. Auwerx. PPAR γ 's fundamental role in adipogenesis. In: Atherosclerosis XIII. Ed. Y. Matsuzawa, T. Kita, R. Nagai, T. Teramoto. Elsevier, 2004, 47-50.

22. L. Fajas, J. Auwerx. Peroxisome proliferator-activated receptor gamma and the transcriptional control of adipogenesis. In: Handbook of Obesity: Etiology and Pathophysiology. Ed. G. A. Bray, C Bouchard. Marcel Dekker, 2004, 559-587.
23. C.A. Argmann, A. Dierich, J. Auwerx General considerations in mouse phenotyping. In: Current Protocols in Molecular Biology. Eds. Assubel, F., Brent, R., Kingston, R.E., Moore, D.M., Seidman, J.G., Smith, J.A., Struhl, K. John Wiley & Sons, 2006, 29A.1.1-29A.2.2.
24. C.A. Argmann, M.F. Champy, J. Auwerx Metabolic exploration of the mouse. In: Current Protocols in Molecular Biology. Ed. Assubel, F., Brent, R., Kingston, R.E., Moore, D.M., Seidman, J.G., Smith, J.A., Struhl, K. John Wiley & Sons, 2006, 29B.1.1-29B1.11.
25. M.F. Champy, C.A. Argmann, P. Chambon, J. Auwerx Exploration of metabolic and Endocrine Function in the mouse. In: Phenotyping of the Laboratory Mouse. Ed. Hrabé de Angelis, M., Chambon, P., Brown, S., Wiley-VCH, Weinheim, 2006, 109-134.

Patents

1. Briggs M, Auwerx J, De Vos P, Staels B, Croston G, Miller SG, inventors; Ligand Pharmaceuticals assignee. *Modulators of ob gene expression and screening methods thereof*. WO9629405. 1996 Sep 26
2. Leibowitz M, Berger J, Moller D, Auwerx J, Berger G, inventors; Merck & Co assignee. *Method for raising HDL cholesterol levels*. WO9728149. 1997 Aug 07
3. Paterniti J, Briggs M, Mukherjee R, Auwerx J, Staels B, inventors; *Ligand Pharmaceuticals assignee*. *Prevention or treatment of cardiovascular disease with PPAR modulators*. WO9805331, 1998 Feb 12
4. Lefebvre AM, Auwerx J, Briggs M, inventors; Ligand Pharmaceuticals assignee. *Treatment of gastrointestinal disorders with PPAR modulators*. WO9843081. 1998 Oct 01
5. Zeng J, Mingfan L, Auwerx J, Fruchart JC, inventors; Institut Pasteur de Lille assignee. *Methods for selecting cDNA fragments*. WO9859070. 1998 Dec 30
6. Briggs M, Saladin R, Auwerx J, Fajas L, inventors; Ligand Pharmaceuticals assignee. *Human PPAR γ gene regulatory sequences and uses thereof*. WO9905161. 1999 Feb 04
7. Mahfoudi A, Benoit P, Branellec D, Deneffe P, Duverger N, Berthou L, Auwerx J, Staels B, inventors; Sanofi-Aventis assignee. *Novel constructs and vectors for the targeted and inducible expression of genes*. US2002144302. 2002 Oct 03
8. Martin. G, Nemoto M, Deeb S, Auwerx J, inventors; Janssen Pharmaceutica assignee. *Nucleotide sequence expressing human fatty acid transporter protein and corresponding amino acid sequence, use for the regulation of fatty acids metabolism*. WO9951740. 1999 Oct 14
9. Rocchi S, Auwerx J, Gelman L, Picard F, Debril MB, inventors; Carex SA assignee. *New nuclear receptor cofactors and related modulators* » AU2002319847. 2002 Dec 03
10. Auwerx J, Chambon P, Picard F, inventors; Carex SA assignee. *Cofactor-based screening method for PPAR γ modulators*. US2003104975. 2003 Jun 05

11. Rocchi S, Auwerx J, VanmecQ J, inventors; Carex, SA assignee. *FMOCL-Leucine and derivatives thereof as PPAR agonist*. US2004082663. 2004 Apr 29
12. Desreumaux P, Dharancy S, Auwerx J, inventors; INSERM assignee. *Screening methods using solid support modified with self assembled monolayers*. US2004171689. 2004 Sep 02
13. Bianco A, Larsen R, Watanabe M, Houten S, Auwerx, J, inventors; Brigham and Women's Hospital assignee. *Methods for increasing cellular energy expenditure*. US patent application 60/667,057; filed 2005 May 11
14. Lagouge M, Argmann C, Elliot P, Millne J, Auwerx J, inventors; Sirtris Pharmaceuticals assignee. *Methods and related compositions for treating or preventing obesity and insulin resistance disorders*. US patent application 60/697,443. 2005 Jul 07
15. Kazuo S, Kaoru S, Shinchu I, Kanami S, Auwerx J, Watanabe M, inventors; Mitsubishi pharmaceuticals assignee. *Preventive and/or therapeutic agents for diabetes*. WO2006041150. 2006 May 20
16. Auwerx J, Frigerio F, Fumigalli S, Sara K, Picard F, Sticker-Janscheff M, George T, Um S, Watanabe M, inventors; Novartis assignee. *Inhibition of S6 Kinase activity for the treatment of insulin resistance*. EP1658504. 2006 May 24
17. Auwerx J, Laakso M, inventors; Sirtris Pharmaceuticals assignee. *Sirtuin polymorphisms and methods of use thereof*. US patent application 11/981,524. 2006 Nov 12
18. Auwerx J, Coste A, O'Malley B, Puigserver P, Lerin C, Louet J.L., inventors; *Means for controlling energy homeostasis through the modulation of PGC-1 activity*. US patent application 60/881,082. 2007 Jan 11